ПРИМЕНЕНИЕ НИТРОКАРБОНОВЫХ КИСЛОТ ДЛЯ ЛЕЧЕНИЯ, ДИАГНОСТИКИ И ПРОФИЛАКТИКИ АГРЕССИВНЫХ ФОРМ ЗАЖИВЛЕНИЯ

Изобретение относится к области медицины и представляет собой покрытие для медицинского устройства, ингибирующее агрессивную форму заживления, содержащее, по меньшей мере, одну нитрокарбоновую кислоту. Изобретение обеспечивает предоставление покрытий для медицинских устройств, которые обладают преимуществами в отношении стабильности, прилипания клеток, роста клеток, биозагрязнения, биосовместимости и биостойкости. 4 з.п. ф-лы, 7 ил., 1 табл., 19 пр.

УЛУЧШЕННОЕ УСТРОЙСТВО И СПОСОБ ДЛЯ ИЗМЕРЕНИЯ МОЧИ

Группа изобретений относится к медицине, а именно к урологии, лабораторной диагностике, и может быть использована при необходимости измерения количества мочи у пациентов с мочевым катетером. Для этого предложена система для измерения, содержащая электронную измерительную систему, включающую электроды, расположенные снаружи измерительной камеры для измерения значений емкости, изменяющихся по мере повышения уровня мочи внутри камеры; и/или измерительная камера для мочи содержит самоопорожняющееся сифонное устройство, выполненное с возможностью самостоятельного опорожнения посредством сливания через сифон. Причем в полостном пространстве системы для измерения мочи расположена капсула со стенками из водорастворимого материала для высвобождения масляной смеси, содержащей 90-100% масла. Предложен способ предотвращения ухудшения функциональности и точности измерения в системе для измерения мочи. Способ включает нанесение масляной смеси на внутренние поверхности системы для измерения мочи. Также ...

ГЛАЗНАЯ ЛИНЗА

Приводится глазная линза, предназначенная для размещения на внешней поверхности глаза. Линза пропитана сложным эфиром многоатомного алифатического спирта и жирной кислоты или содержит его на своей поверхности, при этом фрагмент, образованный алифатическим спиртом, имеет по крайней мере одну гидроксильную группу. Сложный эфир присутствует в количестве, необходимом и достаточном для предотвращения или ослабления выделения бактериальных токсинов в том случае, когда линза подвергается действию указанных токсинов. Линза наиболее приспособлена для мягких контактных линз на основе гидрогеля и обладает преимуществом при устранении, снижении вероятности возникновения и предотвращении кератита. Бактериальный кератит является инфекцией на роговой оболочке глаза, которая может возникнуть при длительном ношении линзы и вызвать поражение роговой оболочки.

BIOVERTRAEGLICHE UND BLUTVERTRAEGLICHE MATERIALIEN UND VERFAHREN ZU DEREN HERSTELLUNG

SAUGFÄHIGE ARTIKEL MIT EINEM SAUREN SUPERABSORBER UND EINEM ORGANISCHEN ZINKSALZ

Delivery of a botanical extract to a treated substrate for transfer to skin

The present invention relates in a combination for surface treatment of a substrate. e.g. a nonwoven web, used in personal care product applications. The surface treatment combination not only provides adequate fluid handling properties, but also provides a topical delivery system effective in depositing a thin, tenacious and substantially continuous coating of a botanical extract on skin by an aqueous emulsion mediated dissolution of the agent from a substrate with subsequent transfer and deposition onto the skin. Coatings of the botanical extract on the skin resist removal, thereby preventing damage to the natural skin barrier and providing a protective barrier against chemically- and biochemically-induced skin damage.

Absorbent articles with non-aqueous compositions containing anionic polymers

The present invention relates to absorbent articles including non-aqueous compositions for protecting the barrier function of the skin. The compositions can be applied to the bodyfacing surfaces of absorbent articles so that the compositions come into contact with the skin. The compositions of the invention have improved stability on the bodyfacing surfaces after processing. The compositions of the invention provide several benefits including prevention and alleviation of skin irritations associated with the use of absorbent articles. The compositions can include emollients, viscosity enhancers and anionic polymers.

A personal care product comprising a botanical extract

Materials and methods for deodorization of mammalian urine

BIOLOGICALLY EFFECTIVE ONES STICKING ARTICLE AND MANUFACTURING PROCESS

Activated polymers binding biological molecules

The present invention relates to activated polymer substrates capable of binding functional biological molecules, to polymer substrates comprising bound and functional biological molecules, to devices comprising such substrates and to methods of producing them.

Personal care article and method for inhibiting attachment of yeast to skin

Resorbable prosthesis for medical treatment

Systems and methods for delivering beneficial agents into targeted tissue of a living being

Absorbent articles with simplified compositions having good stability

MICROSTAMPING ACTIVATED POLYMER SURFACES

WOUND HEALING COMPOSITIONS CONTAINING A PYRUVATE, AN ANTIOXIDANT AND A MIXTURE OF FATTY ACIDS

WETNESS INDICATOR FREE FROM HALOGEN-CONTAINING SPECIES

A hot melt wetness indicator comprising an adhesive base composition utilizing a halogen-free species, namely nitrazine yellow, to trigger color change in hygiene articles, such as disposable diapers, to serve as moisture or wetness indicator upon insult. In some embodiments of the invention, the wetness indicator turns from yellow to purple.

COATING FOR INTRALUMINAL EXPANDABLE CATHETER PROVIDING CONTACT TRANSFER OF DRUG MICRO-RESERVOIRS

A coating for an expandable portion of a catheter comprising a lipophilic matrix and a plurality of micro-reservoirs dispersed in the lipophilic matrix is disclosed. The plurality of micro-reservoirs comprises an active agent. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided.

MEDICAMENT INCORPORATION MATRIX

A coating composition, in both its uncrosslinked and crosslinked forms, for use in delivering a medicament from the surface of a medical device positioned in vivo. Once crosslinked, the coating composition provides a gel matrix adapted to contain the medicament in a form that permits the medicament to be released from the matrix in a prolonged, controlled, predictable and effective manner in vivo. A composition includes a polyether monomer, such as an alkoxy poly(alkylene glycol), a carboxylic acid-containing monomer, such as (meth)acrylic acid, a photoderivatized monomer, and a hydrophilic monomer such as acrylamide.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE VOIDS AND OPEN FRACTURES

The present invention relates to compositions, methods and medical devices for the treatment of bone voids and bone defects. The methods of the invention comprise the step of applying to a bone void or bone defect site a composition comprising a matrix which provides local prolonged release of at least one antibiotic agent at the bone void site.

OSTEOINDUKTIVES BONE SUBSTITUTE AS WELL AS PROCEDURE FOR THE PRODUCTION OF THE SAME.

COMPOSITIONS AND METHODS FOR TREATING SECTIONS OF THE NONEXISTENT OPEN FRACTURES OF BONE TISSUE AND

СПОСОБ ЗАКРЫТИЯ И ЛЕЧЕНИЯ РАНЕВЫХ ПОВЕРХНОСТЕЙ (ВАРИАНТЫ), ПОКРЫТИЕ (ВАРИАНТЫ) И ЛЕЙКОПЛАСТЫРЬ (ВАРИАНТЫ) ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ

... 1. Способ закрытия и лечения раневых поверхностей, заключающийся в том, что на раневой поверхности размещают заживляющее средство, отличающийся тем, что указанное заживляющее средство представляет собой пористый и/или перфорированный слой пчелиного воска, нанесенный на поверхность носителя, либо пчелиный воск, размещенный в порах носителя, либо пчелиный воск в виде пористой и/или перфорированной пленки или предварительно изготовленных гранул. 2. Способ по п.1, отличающийся тем, что для заживляющего средства в виде пчелиного воска на носителе используют носитель из деформируемого материала и деформируют носитель с пчелиным воском для образования в слое пчелиного воска макро- и/или микротрещин. 3. Способ по п.1 или 2, отличающийся тем, что для заживляющего средства в виде пчелиного воска, нанесенного на носитель, используют перфорированный носитель. 4. Способ по любому из пп.1-3, отличающийся тем, что для заживляющего средства в виде пчелиного воска, нанесенного на носитель, используют носитель ...

Method of shaping structures with overcoat layer including female urinary catheter

Gel dressing for wound healing

Sustained release pharmaceutical carrier composition

A KIDNAPPING COMPOSITION OF IRRITATING OF THE SKIN

La presente invencion se refiere a una composicion secuestradora de irritante de la piel que comprende un sustrato, un agente secuestrador de irritante dela piel hidrofílico y un agente secuestrador de irritante de la piel hidrofobico. En una realizacion, los agentes secuestradores están compuestos de arcillasmodificadas, no modificadas, sílice y/o dioxido de titanio. La composicion secuestradora de irritante de la piel puede aglutinar una citoquina y/o eicosanoide.En una realizacion, los irritantes de la piel se aglutinan a los agentes secuestradores presentes en un sustrato. En otra realizacion, los irritantes de lapiel se aglutinan a los agentes secuestradores presentes sobre la piel. En una realizacion adicional, la composicion incluyeasimismo un vehículo para aplicarla composicion.

INHIBITION OF EXOPROTEÍNAS USING ISOPRENÓIDES

TISSUE REINFORCING COMPOSITIONS, DEVICES AND METHODS OF USE

Methods for manipulating and/or reinforcing tissues are provided. The method includes applying a tissue reinforcement material to at least a portion of tissue to be manipulated and applying energy to one or both of the tissue reinforcement material and the tissue.

DEPOSITION OF CALCIUM-PHOSPHATE (CAP) AND CALCIUM-PHOSPHATE WITH BONE MORPHOGENIC PROTEIN (CAP+BMP) COATINGS ON METALLIC AND POLYMERIC SURFACES

The invention is a medical implantable device which is coated by the method according to the invention. The surface of the substrate used for the implantable device, in the raw condition, following a cleaning regime and physiochemical pretreatments, is coated using a biomimetic process in a supersaturated calcium phosphate solution (SCPS) to obtain the desired coating coverage and morphology maintaining a ratio of calcium to phosphorus pH, as well as solution temperature plays a major role in yielding precipitation of the proper phase of CaP so that composition, morphologies, crystal structures, and solubility characteristics are optimal for the deposition process. The biomimetic coating adds the attribute of osteoconductivity to the implant device. To maximize bone growth, the implant must also induce bone growth, or possess the attribute of osteoinductivity. This attribute is acquired by the use of therapeutic agents, i.e. bone morphogenic proteins (BMP), growth factors, stem cells, etc ...

STAND-ALONE FILM AND METHODS FOR MAKING THE SAME

A stand-alone film is derived at least in part from fatty acids. The stand-alone film can have anti-adhesive, anti-inflammatory, non-inflammatory, and wound healing properties, and can additionally include one or more therapeutic agents incorporated therein. Corresponding methods of making the stand-alone film include molding, casting, or otherwise applying a liquid or gel to a substrate, and curing or otherwise treating to form the stand-alone film. The resulting stand-alone film is bioabsorbable.

ABSORBENT ARTICLES WITH NON-AQUEOUS COMPOSITIONS CONTAINING BOTANICALS

The present invention relates to absorbent articles including non-aqueous compositions for protecting the barrier function of the skin. The compositions can be applied to the bodyfacing surfaces of absorbent articles so that the compositions come into contact with the skin. The compositions of the invention have improved stability on the bodyfacing surfaces after processing. The compositions of the invention provide several benefits including prevention and alleviation of skin irritations associated with the use of absorbent articles. The compositions can include emollients, viscosity enhancers and extracted botanical actives.

MEDICAMENT INCORPORATION MATRIX

A coating composition, in both its uncrosslinked and crosslinked forms, for use in delivering a medicament from the surface of a medical device positioned in vivo. Once crosslinked, the coating composition provides a gel matrix adapted to contain the medicament in a form that permits the medicament to be released from the matrix in a prolonged, controlled, predictable and effective manner in vivo. A composition includes a polyether monomer, such as an alkoxy poly(alkylene glycol), a carboxylic acid-containing monomer, such as (meth)acrylic acid, a photoderivatized monomer, and a hydrophilic monomer such as acrylamide.

BRANCHED POLYTHYLENE OXIDE TERMINATED BIOMEDICAL POLYMERS AND THEIR USE IN BIOMEDICAL DEVICES

A biomedical polymer has a substantially linear base polymer; and branched polyethylene oxide covalently bonded to the base polymer as surface active end groups. The branched polyethylene oxide has at least two, more particularly at least four, and still more particularly at least six branches. Suitable base polymers include epoxies, polyurethanes, polyurethane copolymers,fluoropolymers, polyolefins and silicone rubbers. Biologically active agents may be attached to the branched polyethylene oxide. Suitable biologically active agents include microbial peptide agents, detergents, non-steroidal anti-inflammatory drugs, cations, amine-containing organosilicones, diphosphonates, fatty acids, fatty acid salts, heparin and glucocorticosteroids. The biological polymer may be used as a casing for a medical unit of an implantable medical device, such as a pacemaker. In this case, the casing at least partially encloses the medical unit.

ABSORBENT ARTICLE WHICH MAINTAINS OR IMPROVES SKIN HEALTH

L'invention concerne un article absorbant comprenant une couche inférieure perméable aux vapeurs, une couche supérieure perméable aux liquides située face à la couche inférieure, et un corps absorbant placé entre la couche inférieure et la couche supérieure. Le corps absorbant peut comporter des zones multiples de perméabilité à l'air élevée. L'article absorbant peut également inclure une couche respirante située entre le corps absorbant et la couche inférieure, et une couche répartissant les liquides, située entre le corps absorbant et la couche supérieure. Les échanges d'air sont améliorés à l'intérieur de l'article, lors de son utilisation. En conséquence, l'article permet de maintenir la température et de diminuer sensiblement les niveaux d'hydratation cutanée chez l'utilisateur, la peau étant alors moins sensible à la viabilité des micro-organismes. L'article absorbant peut, en outre, contenir des préparations de lotions et/ou des compositions de traitement permettant de protéger ou ...

Stand-alone film and methods for making the same

A stand-alone film is derived at least in part from fatty acids. The stand-alone film can have anti-adhesive, anti-inflammatory, non-inflammatory, and wound healing properties, and can additionally include one or more therapeutic agents incorporated therein. Corresponding methods of making the stand-alone film include molding, casting, or otherwise applying a liquid or gel to a substrate, and curing or otherwise treating to form the stand-alone film. The resulting stand-alone film is bioabsorbable.

Application of a coating on a medical device

Devices for the provision of a coating on an implantable medical device are provided. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a therapeutic agent component can also be provided. The devices provide a coating having improved uniformity and coverage which in turn allow for greater control of the amount and dosage of the coating.

Body fluid drainage device and method

Method for sterilizing a body fluid drainage system for handling a body fluid ex vivo. The body fluid drainage system comprises a chamber. The method comprises the steps providing a container containing a surface protective fluid to be released into the chamber of the body fluid drainage system, subjecting the container to radiation sterilization, inserting the container into the chamber of the body fluid drainage system, and subjecting the chamber containing the container to gas sterilization. A body fluid drainage system for handling a body fluid ex vivo. The body fluid drainage system comprises a chamber. The body fluid drainage system further comprises a container containing a surface protective fluid. The container is arranged to release the surface protective fluid into the chamber. The surface protective fluid is sterilized by radiation sterilization. An outer surface of the container and at least the chamber of the body fluid drainage system is sterilized by gas sterilization.

Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids

The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.

ОДНОРАЗОВОЕ АБСОРБИРУЮЩЕЕ ИЗДЕЛИЕ, ТАМПОН (ВАРИАНТЫ), СПОСОБ ИЗГОТОВЛЕНИЯ ОДНОРАЗОВОЙ АБСОРБИРУЮЩЕЙ ПОДЛОЖКИ, СПОСОБ ИЗГОТОВЛЕНИЯ ОДНОРАЗОВОГО АБСОРБИРУЮЩЕГО ИЗДЕЛИЯ (ВАРИАНТЫ), РАСТВОР ДЛЯ ИЗГОТОВЛЕНИЯ ОДНОРАЗОВОГО АБСОРБИРУЮЩЕГО ИЗДЕЛИЯ

Изобретение относится к медицинским и гигиеническим средствам. Фармацевтически активное соединение наносят на подложки. Оно выбрано из группы, состоящей из сложных моноэфиров многоатомного алифатического спирта и жирной кислоты, содержащей от восьми до восемнадцати углеродных атомов, причем указанный моноэфир имеет по крайней мере одну гидроксильную группу, связанную с его алифатическим спиртовым остатком; сложных диэфиров многоатомного алифатического спирта и жирной кислоты, содержащей от восьми до восемнадцати углеродных атомов, причем указанный диэфир имеет по крайней мере одну гидроксильную группу, связанную с его алифатическим спиртовым остатком, и смесей указанных сложных моноэфиров и диэфиров. Одноразовое абсорбирующее изделие содержит раствор, жидкий при toC<35o С. Указанные фармацевтически активные соединения наносят на подложки и изделия в виде раствора. Изобретение позволяет создать покрытие, устойчивое при температуре выше комнатной, но становящееся жидким при температуре тела ...

ВПИТЫВАЮЩИЕ ИЗДЕЛИЯ, ВКЛЮЧАЮЩИЕ КИСЛОТНЫЙ СУПЕРВПИТЫВАЮЩИЙ МАТЕРИАЛ И ОРГАНИЧЕСКУЮ СОЛЬ ЦИНКА

Настоящее изобретение относится к медицине, конкретно к впитывающему изделию, такому как подгузники, подгузники-трусики, гигиенические прокладки или приспособления при недержании, включающему влагопроницаемый передний слой, влагонепроницаемый задний слой и впитывающий внутренний слой, расположенный между указанным влагопроницаемым передним слоем и указанным влагонепроницаемым задним слоем, где указанный впитывающий внутренний слой включает супервпитывающий материал, характеризующийся тем, что указанный супервпитывающий материал представляет собой кислотный супервпитывающий материал, имеющий рН 5,5 или меньше, при этом впитывающий внутренний слой дополнительно включает органическую соль цинка, в частности рицинолеат цинка. Комбинация органической соли цинка и кислотного супервпитывающего материала проявляет синергетический эффект при подавлении образования основных соединений с неприятным запахом, таких как аммиак. Впитывающее изделие содержит эффективную систему контроля запаха. 11 з.п.

ДРЕНАЖНОЕ УСТРОЙСТВО ДЛЯ БИОЛОГИЧЕСКИХ ЖИДКОСТЕЙ И СПОСОБ ЕГО СТЕРИЛИЗАЦИИ

Группа изобретений относится к области стерилизации медицинских изделий. Раскрыт способ стерилизации дренажной системы для биологических жидкостей для обработки биологической жидкости ex vivo, согласно которому подвергают контейнер стерилизации облучением; вставляют контейнер в камеру дренажной системы для биологических жидкостей; и подвергают камеру, содержащую контейнер, стерилизации газом. При этом дренажная система для биологических жидкостей содержит камеру и контейнер, содержащий защищающую поверхность жидкость, выпускаемую в камеру дренажной системы для биологических жидкостей, причем защищающая поверхность жидкость прилипает к поверхности камеры и предотвращает контакт других жидкостей с поверхностью. Также раскрывается вариант способа стерилизации дренажной системы для биологических жидкостей для обработки биологической жидкости ex vivo. Группа изобретений обеспечивает стерилизацию дренажной системы, которая может храниться в течение длительного времени. Раскрытые способы дают ...

УЛУЧШЕННЫЕ ПОКРЫТЫЕ СЛОЕМ ЛЕКАРСТВЕННОГО ВЕЩЕСТВА МЕДИЦИНСКИЕ ИЗДЕЛИЯ, ИХ ИЗГОТОВЛЕНИЕ И ПРИМЕНЕНИЕ

... 1. Баллонный катетер, содержащий баллон катетера с гидрофильной или гидрофилизированной мембраной баллона, причем мембрана баллона покрыта по меньшей мере одним лежащим открыто на поверхности активным веществом таким образом, что при расширении баллона катетера по меньшей мере одно активное вещество немедленно высвобождается. ! 2. Баллонный катетер по п.1, в котором мембрана баллона катетера обработана активированным кислородом. ! 3. Баллонный катетер по п.1 или 2, в котором баллон катетера дополнительно покрыт произвольными вспомогательными веществами. ! 4. Баллонный катетер по п.1, причем радиус баллона катетера после полного разворачивания с помощью повышенного давления внутри баллона катетера увеличивается более чем на 15%, предпочтительно более чем на 30% и особенно предпочтительно более чем на 60%. ! 5. Баллонный катетер с по меньшей мере одним лежащим открыто на поверхности активным веществом, которое немедленно высвобождается при расширении баллона катетера, при этом радиус баллона ...

OF LENS WITH A MEANS AGAINST TOXINE

Activation of growth factors by matrix vesicles

Facial tissue composition and method of use for sequestration of nasal secretion skin irritants

Implant therapy for bone growth stimulation

Biofunctional fibers

Methods for coating implant surfaces to treat surgical infections

Methods for treating infection at the site of implantation of an orthopedic device in a human or animal subject. The methods include removing the orthopedic device, and implanting a replacement device. A surface of the replacement device is coated with an infection-inhibiting composition having a waxy matrix. The waxy matrix includes an infection-inhibiting material, such as a lipid, an antimicrobial agent, or a combination of a lipid and an antimicrobial agent.

Absorbent article with odour control substane

COMPOSITIONS AND METHODS TO TREAT URINARY TRACT INFECTIONS

This invention relates to treating and preventing urinary tract infections. Glycerol monolaurate (GML) and/or GML-related compositions together with suitable accelerants in gel-based formulation may be used to treat urinary tract infections that may be generally diagnosed, for example, in women, catheterized patients and elderly individuals. Such a gel-based formulation kills, or inhibits the growth of, one or more pathogenic microorganisms that cause urinary tract infections.

ANTIMICROBIAL FATTY ACID CONTAINING SUTURE COATING

Compositions with antimicrobial properties contain a metal salt of a fatty acid mixed a bioabsorbable copolymer. These compositions are useful in forming coatings for surgical articles, including multifilament sutures.

LIPID-BASED SUSTAINED-RELEASE DRUG CARRIER MATRIX

The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block- co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.

OPHTHALMIC LENS WITH ANTI-TOXIN AGENT

An ophthalmic lens for placement on the anterior surface of the eye is disclosed. The lens has impregnated in it or it has coated on its surface an ester of a polyhydric aliphatic alcohol and a fatty acid in which the alcohol residue has at least one hydroxyl group. The ester is present in an amount which is effective to prevent or decrease the release of bacterial toxins when the lens is exposed to those toxins. The lens is particularly well-suited for a soft hydrogel contact lens, and advantageously eliminates, minimizes or prevents keratitis. Bacterial keratitis is an infection of the cornea of the eye which may occur during extended wear of the lens and may cause ulceration of the cornea.

WOUND HEALING COMPOSITIONS CONTAINING A PYRUVATE, AN ANTIOXIDANT AND A MIXTURE OF FATTY ACIDS

... 2123678 9310776 PCTABS00022 The present invention pertains to therapeutic wound healing compositions. The compositions comprise (a) pyruvate selected from the group consisting of pyruvic acid, pharmaceutically acceptable salts of pyruvic acid, and mixtures thereof, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids wherein the fatty acids are those fatty acids required for repair of cellular membranes and resuscitation of mammalian cells. The therapeutic compositions may be utilized in a wide variety of topical and ingestible pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic compositions and the topical pharmaceutical products in which the therapeutic compositions may be used.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE VOIDS AND OPEN FRACTURES

Improved pharmaceutical-coated medical products, the production thereof and the use thereof

formulação à base de gel para tratar ou prevenir infecção do trato urinário, composição, métodos para tratamento ou profilaxia e para tratar ou prevenir uma infecção do trato urinário, cateter urinário ou dispositivo de demora, e, formulação à base de gel

NASAL, WOUND AND SKIN FORMULATIONS AND METHODS FOR CONTROL OF ANTIBIOTIC-RESISTANT STAPHYLOCOCCI AND OTHER GRAM-POSITIVE BACTERIA

Formulations and methods are disclosed which are effective to kill or control bacteria in the nares including gram-positive bacteria strains of S. aureus that are antibiotic resistant (MRSA - methicillin-resistant Staphylococcusaureus. A preferred composition comprises one or more medium-chain alcohols (dodecanol), glycerol monoesters (glycerol monocaprylate or glycerol monolaurate), and/or benzoic acid or benzoic acid analog, in a suitable pharmaceutical carrier, preferably an ointment, along with an odorant compound, preferably eucalyptus oil. The formulations and variations of the formulation may also be used on open wounds or lesions as well as intact skin.

DELIVERY OF A BOTANICAL EXTRACT TO A TREATED SUBSTRATE FOR TRANSFER TO SKIN

L'invention porte sur une combinaison de traitements de surface d'un substrat, par exemple une bande de non tissé utilisé dans des produits d'hygiène corporelle. Lesdits traitements confèrent non seulement des propriétés adéquates de traitement des fluides, mais servent également de moyen d'application sur la peau d'un revêtement mince, tenace, et sensiblement continu d'un extrait botanique fait d'une dissolution de protéines médiée par une émulsion aqueuse de l'agent préalablement déposé sur un substrat d'où il est transféré sur la peau. Ces revêtements d'extrait botanique disposés sur la peau résistent à l'arrachement et constituent de ce fait une barrière protectrice contre les agressions chimiques et biochimiques de la peau.

Urine measurement device and method

A urine handling system capsule (105) for releasing an oil mixture in the lumen of a urine handling system, the capsule (105) comprising a capsule wall defining a space filled with an oil mixture, wherein the oil mixture comprises 90-100% of an oil selected from the group consisting of silicone fluids and mineral oils or a mixture thereof, and having a viscosity of at most 600 cSt, and wherein the capsule wall is made of a water-soluble material. A urine measurement system (101) comprising an oil mixture arranged in the luminal space of the measurement system. A method for inhibiting impairment of functionality and measurement accuracy in a urine measurement system comprising applying an oil mixture to the inner surfaces of the urine measurement system. Use of an oil mixture in treatment of luminal surfaces of a urine handling system.

Lyophilized moldable implants containing an oxysterol

Provided is a lyophilized implant configured to fit at or near a bone defect to promote bone growth, the lyophilized implant containing a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant, mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant, and an oxysterol in an amount of about 5 wt. % to about 90 wt. % of the implant. Methods of making and using the implant are further provided.

Liposomal formulation for joint lubrication

The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20° C. to about 39° C. and the joint has a joint temperature which is above the phase transition temperature.

Anti-infective antimicrobial-containing biomaterials

A material including a plurality of fatty acid chains cross-linked together and a silver fatty acid salt formed with the fatty acid chains within the material. Methods for forming a material are also included. The silver-containing materials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents.

Improved pharmaceutical-coated medical products, the production thereof and the use thereof

Die vorliegende Erfindung betrifft neue Kombinationen von Ballonkathetern und an der Oberfläche der Ballonmembran haftenden Wirkstoffzubereitungen. Des Weiteren betrifft die vorliegende Erfindung Beschichtungsverfahren zur Herstellung dieser Ballonkatheter sowie deren Verwendung zur Behandlung und Prophylaxe von Gefäßerkrankungen.

УЛУЧШЕННОЕ УСТРОЙСТВО И СПОСОБ ДЛЯ ИЗМЕРЕНИЯ МОЧИ

Система и устройство дл предотвращени повторного стеноза в сосудах тела

... 1. Система для предотвращения повторного стеноза после процедуры вмешательства в сосуде или полости тела, имеющем поверхность внутренней стенки, содержащая введение устройства, покрытого останавливающим рост выделенным из липидов биоактивным веществом или его производным в желательном месте на поверхности внутренней стенки сосуда или полости тела. 2. Система по п.1, в которой упомянутое устройство является катетером или стентом. 3. Система по п.1, в которой упомянутое останавливающее рост выделенное из липидов биоактивное вещество выбирается из группы, состоящей из керамида, диметил сфингозина, эфирно-связанных диглицеридов, эфирно-связанных фосфатидных кислот и сфинганинов или их производных. 4. Система по п.3, содержащая далее шаги: (а) введение терапевтического устройства, содержащего останавливающее рост выделенное из липидов биоактивное вещество, в желательное место на поверхности внутренней стенки; (б) размещение устройства в части сосуда или полости с поврежденной или заболевшей ...

VERFAHREN ZUM FORMEN VON STRUKTUREN MIT EINER DECKUNGSSCHICHT INKLUSIVE WEIBLICHEN HARNKATHETER

Substrat, welches mit einer Zusammensetzung behandelt ist, die einen botanischen Extrakt und ein Tensid enthält, sowie Körperpflegeartikel, welcher das behandelte Substrat enthält

Mit einer Zusammensetzung behandeltes Substrat, wobei die Zusammensetzung ein Tensid und einen botanischen Extrakt enthält, und wobei das Tensid eine Verbindung umfasst, ausgewählt aus ethoxylierten hydrierten Fettölen, Monosacchariden und einer Kombination davon, und der botanische Extrakt ausgewählt ist aus Avocadoöl, Karottenöl, Sesamöl und Paranussöl.

Verfahren zur Hinzufügung pharmazeutisch wirksamer Verbindungen zu Substraten

Hemostatic agent, useful to coat medical implant, comprises a saturated glycerol-1,2,3-trifatty acid ester, a filler, which is partially in particulate form and a compound with specified melting temperature and solubility

Plastically deformable, biodegradable hemostatic agent comprises (a) at least one saturated glycerol-1,2,3-trifatty acid ester with a melting temperature of greater than 37[deg] C, (b) at least one filler (which is partially in particulate form) having a melting temperature of greater than 37[deg] C and (c) at least a compound with melting temperature of = 37[deg] C and a solubility of less than 50 g/l of water at 25[deg] C. An independent claim is included for forming the plastically deformable, biodegradable hemostatic agent hemostatic agent comprising providing the hemostatic agent, heating the hemostatic agent at 35-40[deg] C and forming the plastically deformable, biodegradable hemostatic agent.

BIOMEDIZINISCHE POLYMERE MIT VERZWEIGTEM POLYETHYLENOXID-ENDE UND IHRE VERWENDUNG IN BIOMEDIZINISCHEN VORRICHTUNGEN

Water soluble farnesol analogs and their use

Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).

Healing

MATRIX FOR THE ADMISSION OF DRUGS

COMPOSITION FOR ADSORBING BACTERIA.

CATHETER WITH HYDROPHILIC ANTHRACHINON HALTIGER COATING

Breast pad assembly containing a skin benefit ingredient

Methods of performing medical procedures which promote bone growth, compositions which promote bone growth, and methods of making such compositions

ANTIMICROBIAL FATTY ACID CONTAINING SUTURE COATING

Sustained-release drug carrier composition

The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block- co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.

Functionalizing nanofibres

Methods for functionalizing the surface of nanofibre substrates, including electrospun fibres and non-woven or woven mats of fibres are described. Functionalised nanofibre substrates presenting biologically active moieties such as biotin and saccharides are described.

Method of shaping structures with an overcoat layer including female urinary catheter

Method of shaping structures with an overcoat layer including female urinary catheter

Catheter system for controllably releasing a therapeutic agent at a remote tissue site

BIO-COMPATIBLE AND BLOOD COMPATIBLE MATERIALS AND METHODS

BACTERIA ADSORBING COMPOSITION

A bacteria adsorbing composition which includes a first component comprising a powerfully hydrophobic, bacteria adsorbing, physiologically innocuous, preferably water-insoluble material, and a second component comprising a hydrophilic, liquid absorbing, physiologically innocuous material.

ANTIMICROBIAL SURFACE TREATMENT

A method of surface treating surgical dressings and implants to reduce the likelihood of post-operative infection and synthetic, water dispersible lipid constructs for use in the method are disclosed. In a first aspect the invention provides an antimicrobial surface treatment method comprising the step of contacting the surface of an object with an aqueous dispersion of at least one functional-lipid construct where the lipid is a di-acyl, di-alkenyl or di-alkyl glycerophospholipid and the functional moiety of the construct confers the antimicrobial activity.

SUSTAINED RELEASE FILM PREPARATION FOR LOCAL ADMINISTRATION COMPRISING PROSTAGLANDIN DERIVATIVE AS ACTIVE INGREDIENT

A persistent filmy preparation which comprises methyl (11.alpha.,13E,15.alpha.)-9-oxo-11,15-dihydroxy-16-(3-methoxymethylphenyl)- 17,18,19,20-tetranor-5-thiaprost-13-enoate represented by the formula (I): (I) or a nontoxic salt thereof as an active ingredient and a bioabsorbable polymer as a substrate and which is for use in topical administration to a sick location where the bone amount is small; and a remedy for bone amount reduction which comprises the persistent filmy preparation. The persistent filmy preparation, which contains the compound (I) as an active ingredient, promotes bone formation upon topical administration and is useful for treatments for bone amount reduction.

HIGHLY ABSORBENT RESISTANT WASHABLE AND REUSABLE UNDERGARMENTS, METHODS OF USE, KITS AND USES THERETO

An undergarment article has a fabric a fabric layer for wearing about a pelvic region of a person, a water-repellent layer coupled to a crotch portion of the fabric layer to form an inner chamber, and an inner pad disposed within the inner chamber between the water-repellent layer and the fabric layer. The inner pad is resistant to heat and includes a liquid-absorbent layer and a waterproof layer. The liquid-absorbent layer contacts the water-repellent layer and is effective for absorbing a volume of liquid greater than 2 fluid ounces. The waterproof layer is effective for restricting liquid from reaching the fabric layer. The crotch portion of the fabric layer and the water-repellent layer can be substantially elastic in at least one of a lateral direction and a longitudinal direction of the crotch portion. Methods for using the undergarment, kits and uses of the undergarment are also disclosed.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE VOIDS AND OPEN FRACTURES

The present invention relates to compositions, methods and medical devices for the treatment of bone voids and bone defects. The methods of the invention comprise the step of applying to a bone void or bone defect site a composition comprising a matrix which provides local prolonged release of at least one antibiotic agent at the bone void site.

NITRIC OXIDE RELEASING PHARMACEUTICAL COMPOSITIONS

The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same.

METHOD OF SHAPING STRUCTURES WITH AN OVERCOAT LAYER INCLUDING FEMALE URINARY CATHETER

A method of shaping polymeric structures by coating a support structure with a bond-preventing agent to attain a particular shape and subsequently coating the shaped structure of the bond-preventing agent with a polymeric bonding composition is provided. Such shaped polymeric structures can have one or more cavities (16) which can be fluid-filled or gel-filled. Also provided is a handactuating retention female urinary catheter (5) having an inner tube (12) and an outer overcoat layer (14) encircling the tube with an elastomeric collar (50) with a shroud (51). A cavity (16) containing a fluid (18) is interposed between the tube (12) and the overcoat layer (14). The cavity includes a balloon portion (24) and a reservoir portion (22). The shroud (51) encircles the reservoir section (22) to inhibit the ballooning of the reservoir section when the reservoir section is squeezed to force fluid (18) from the reservoir portion (22) to the balloon portion (24) through the sleeve portion (34) of the ...

POLYMER-COATED STENTS, PROCESSES FOR PRODUCING THE SAME AND THEIR USE FOR RESTENOSIS PREVENTION

Polymer-coated stents, processes for producing the same and their use for restenosis prevention are disclosed.

ADDING PHARMACEUTICALLY ACTIVE COMPOUNDS TO SUBSTRATES

The present invention relates to a low temperature process for adding pharmaceutically active compounds to substrates. The substrates are preferably those used in the manufacture of disposable absorbent articles, or are the articles themselves. The pharmaceutically active compound is selected from the group consisting of: monoesters of a polyhydric aliphatic alcohol and a fatty acid containing from eight to eighteen carbon atoms and wherein said monoester has at least one hydroxyl group associated with its aliphatic alcohol residue; diesters of a polyhydric aliphatic alcohol and a fatty acid containing from eight to eighteen carbon atoms and wherein said diester has at least one hydroxyl group associated with its aliphatic alcohol residue; and mixtures of said monoesters and diesters.

RAW MATERIAL FOR BIO-3D PRINTING SUPPORT, AND METHOD FOR MANUFACTURING THREE-DIMENSIONAL SUPPORT USING SAME

The present invention relates to a raw material for a bio-3D printing support. More particularly, the present invention relates to a new type of a material for tissue engineering for bio-3D printing support, a method for manufacturing a three-dimensional support using the same, and a 3D printing three-dimensional support manufactured thereby, wherein a natural fatty acid and a fatty alcohol (phase change material) having a low melting point and a low molecular weight are used as a raw material for a tissue engineering support (scaffold) by a bio-3D printing technology to realize non-toxicity, excellent biocompatibility and cell adhesion, and in particular, a phase change occurs at a temperature similar to a body temperature to simplify the process and enable incorporation of cells or growth factors. COPYRIGHT KIPO 2018 ...

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Antimicrobial compounds having protective or therapeutic leaving groups

Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents.

Peg based hydrogel for peripheral nerve injury applications and compositions and method of use of synthetic hydrogel sealants

Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.

Antimicrobial disposable absorbent articles

Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth.

Progesterone-containing compositions and devices

Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the invention provides a drug eluting device, such as a drug eluting stent, with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices.

Method for Reducing or Preventing Transplant Rejection in the Eye and Intraocular Implants for Use Therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Apparatus and methods for filling a drug eluting medical device via capillary action

Methods and apparatus are disclosed for filling a therapeutic substance or drug within a hollow wire that forms a stent. The stent is placed within a chamber housing a fluid drug formulation. During filling, the chamber is maintained at or near the vapor-liquid equilibrium of the solvent of the fluid drug formulation. To fill the stent, a portion of the stent is placed into contact with the fluid drug formulation until a lumenal space defined by the hollow wire is filled with the fluid drug formulation via capillary action. After filling is complete, the stent is retracted such that the stent is no longer in contact with the fluid drug formulation. The solvent vapor pressure within the chamber is reduced to evaporate a solvent of the fluid drug formulation. A wicking means may control transfer of the fluid drug formulation into the stent.

Loading and release of water-insoluble drugs

A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

FORMATION OF SEMI-PERMEABLE POROUS ARTIFICAL SCAB

Pourous semi-ermeable artificial self-attaching scab designed to protect the eroded or injured surfaces. 1. (canceled)2. An aqueous thixotropic fluid , comprising:1-5 weight % of azosulfamide, 0.004-0.007 weight % of gentian violet, 0.001-0.003 weight % of dexamethasone, 0.5-2 weight % of panthenol, and 0.03-0.06 weight % of gentamycin.3. The fluid according to claim 2 , wherein it is used topically as cicatrizing agent.4. The fluid according to claim 2 , wherein it is used for treating at least one of lesions claim 2 , wounds or burns. The present invention relates to artificial cicatrization means by means of which a substance is applied to the damaged surfaces, wounds, burns A-AB, after removing the necrotic tissue and disinfecting the damaged or burnt zone.The technique consists of the removal of the necrotic tissue from the injured zone and subsequent application of the artificial covering mentioned in the title. The preparation causes the formation of an artificial scab on the injured surface.The problems to be solved are:1. To replace the use of gauzes since they adhere to the damaged zone and cause lesions in the granulation zone when an attempt is made to remove them, thus causing defective cicatrizations.2. To avoid potential infections given that protection against external biological agents is provided.3. To avoid the loss of body fluids and heat, resulting from the loss of the integrity of the mechanical barrier.The porous artificial scab allows the formation of new tissue, allowing its natural respiration: during its regeneration and bringing about a faster development of cicatrization by avoiding disrupted processes such as the necrosis or the development of anaerobes, without the need to cover and without performing further treatments until the natural detachment of the “Scab.”*To protect the lesion against infections and losses of fluids with an artificial scab, and thus the cicatrization is much more rapid and the new tissue is not defective.*The ...

COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USE

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth, the compression resistant implant comprising porous ceramic particles in a biodegradable polymer, and an oxysterol disposed in or on the compression resistant implant. Methods of making and use are further provided. 1. A compression resistant implant configured to fit at or near a bone defect to promote bone growth , the compression resistant implant comprising porous ceramic particles in an amount of about 30 wt % to about 99.5 wt % in a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % based on a total weight of the implant , and an oxysterol disposed in or on the compression resistant implant.2. An implant according to claim 1 , wherein the implant is not compressed any more than about 20% in any one direction for a period of at least about 30 days in vivo.3. An implant according to claim 1 , wherein (i) the porous ceramic particles are uniformly distributed throughout the implant; (ii) the oxysterol is uniformly distributed throughout the biodegradable polymer; and/or (iii) the oxysterol is uniformly distributed throughout the porous ceramic particles.4. An implant according to claim 1 , wherein the porous ceramic particles form a ceramic skeleton claim 1 , the skeleton having pores in the range of 1-10 mm in diameter claim 1 , and a total porosity of 50-98%.5. An implant according to claim 1 , wherein the implant comprises autograft claim 1 , allograft and/or xenograft bone particles.6. An implant according to claim 1 , wherein the biodegradable polymer comprises porcine-derived collagen claim 1 , human-derived collagen claim 1 , bovine-derived collagen claim 1 , piscine-derived collagen claim 1 , ovine-derived collagen claim 1 , recombinant collagen claim 1 , gelatin claim 1 , or combinations thereof.7. An implant according to claim 1 , wherein (i) the porous ceramic particles comprise bone powder claim 1 , demineralized bone ...

Implants having a high drug load of an oxysterol and methods of use

Provided is an implant configured to fit at or near a bone defect to promote bone growth, the implant comprising: a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and an oxysterol in an amount of about 20 wt % to about 90 wt % of the implant. The implant has a high oxysterol load. Methods of making and use are further provided.

BARRIER LAYER

A barrier layer and corresponding method of making provide anti-inflammatory, non-inflammatory, and anti-adhesion functionality for a medical device implantable in a patient. The barrier layer can be combined with a medical device structure to provide anti-adhesion characteristics, in addition to improved healing, non-inflammatory, and anti-inflammatory response. The barrier layer is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil, that is at least partially cured forming a cross-linked gel. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent. 145-. (canceled)46. A method of making a barrier layer device , the method comprising the steps of:providing a medical device structure; andcreating a barrier layer formed on at least a portion of the medical device structure; wherein the barrier layer is formed of a biological oil or oil composition comprising a cured fish oil, wherein the cured fish oil comprises fatty acids and glycerides, wherein two or more of the fatty acids are cross-linked to each other by ester bonds in a substantially random configuration, wherein the barrier layer is solid but flexible and serves as a physical barrier, and wherein the barrier layer degrades into non-inflammatory substances.47. The method of claim 46 , wherein creating the barrier layer comprises:providing a biological oil or oil composition;applying the oil or oil composition to the medical device structure; andcuring the oil or oil composition on the medical device structure to form the barrier layer.48. The method of claim 47 , further comprising partially curing the biological oil or oil composition prior to applying the oil or oil composition to the medical device structure to thicken the oil or oil composition.49. The method of claim 46 , further comprising applying the oil or oil composition using multiple tiers.50. The method of claim 46 , further ...

Antimicrobial disposable absorbent articles

Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth.

BONE TISSUE ENGINEERING BY EX VIVO STEM CELLS ONGROWTH INTO THREE-DIMENSIONAL TRABECULAR METAL

Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue. 1. (canceled)2. A method of generating tissue , comprising:providing or obtaining a tissue scaffold implant comprising a shaped, porous three-dimensional tissue scaffold with an inert biocompatible metal film present on surfaces of the porous three-dimensional tissue scaffold and with living cells in pores of the porous three-dimensional tissue scaffold, said porous three-dimensional tissue scaffold having an interconnected porosity for facilitating nutrient diffusion and media circulation throughout the porous three-dimensional tissue scaffold; andplacing said tissue scaffold implant in an ex-vivo bioreactor for generating tissue on said porous three-dimensional tissue scaffold.3. The method of claim 2 , wherein said tissue scaffold implant is shaped and sized as an acetabular cup implant.4. The method of claim 2 , wherein said porous three-dimensional tissue scaffold has a porosity of 50% to 90%.5. The method of claim 2 , wherein said inert biocompatible metal film is a chemical vapor deposited metal film.6. The method of claim 2 , wherein said living cells comprise mesenchymal stem cells.7. The method of further comprising at least one substance on surfaces of the inert biocompatible metal film that is present on surfaces of the porous three-dimensional tissue scaffold with ...

FUNCTIONALIZATION OF BIOMATERIALS TO CONTROL REGENERATION AND INFLAMMATION RESPONSES

The inventions provided herein generally relate to compositions and methods for controlling response of immune cells to at least one stimulus or condition (e.g., but not limited to, tissue damage, an implantable device and/or a cytokine) in vitro or in vivo. The compositions described herein comprise a biomaterial (e.g., a silk fibroin-based matrix) comprising at least one immune cell-modulating agent in an effective amount sufficient to selectively alter activation state of at least one type of immune cells (e.g., but not limited to macrophages and dendritic cells). Accordingly, in some embodiments, the compositions and methods described herein can be used to selectively skew macrophages to M1 phenotype and/or M2 phenotype and thereby control the inflammatory and/or regenerative responses of the macrophages, e.g., to repair and/or regenerate a target tissue. 1. A composition comprising a biomaterial comprising at least one immune cell-modulating agent in an effective amount sufficient to selectively alter activation state of at least one type of immune cell upon contact with said at least one immune cell-modulating agent.2. The composition of claim 1 , wherein said at least one type of the immune cell is selected from the group consisting of monocytes claim 1 , macrophages claim 1 , dendritic cells claim 1 , megakaryocytes claim 1 , granulocytes claim 1 , T cells claim 1 , B cells claim 1 , natural killer (NK) cells claim 1 , and any combinations thereof.3. (canceled)4. (canceled)5. The composition of claim 1 , wherein the biomaterial is adapted for a sustained release of said at least one immune cell-modulating agent.6. The composition of claim 1 , wherein the biomaterial comprises at least two immune cell-modulating agents.7. The composition of claim 6 , wherein the biomaterial is adapted to release a first immune cell-modulating agent and a second immune cell-modulating agent at different time points.8. The composition of claim 7 , wherein the biomaterial ...

AMPHIPHILIC DEGRADABLE POLYMERS FOR IMMOBILIZATION AND SUSTAINED DELIVERY OF BIOMOLECULES

The invention provides a novel approach to controlled delivery of biomolecules (e.g., lipids and proteins) by employing novel amphiphilic polymers that are effective delivery vehicles. These unique amphiphilic polymers may be employed as controlled delivery vehicles or tissue engineering scaffolds wherein the delivery of lipophilic or amphiphilic bioactive molecules can be achieved. An amphiphilic biodegradable polymer platform is disclosed herein for the stable encapsulation and sustained release of biomolecules, such as S1P. 1. An amphiphilic degradable block copolymer , comprisinghydrophilic blocks;lipophilic blocks; and{'sub': 6', '24, 'lipophilic blocks having pendent alkyl chains of lengths from about Cto about C.'}4. The amphiphilic degradable block copolymer of claim 3 ,{'sub': 1', '2, 'each of Rand Ris a methyl group;'}{'sub': 12', '18, 'R is a linear alkyl chain of a length from about Cto about C;'}i is an integer from about 200 to about 800;each m is an integer from about 10 to about 100; andeach n is an integer from about 100 to about 500.5. The amphiphilic degradable block copolymer of claim 4 , wherein the ratio of i:m:n ranges from about 1˜50:1˜50:1˜50 to about 50˜1:50˜1:50˜1.6. The amphiphilic degradable block copolymer of claim 1 , having a molecular weight from about 10 claim 1 ,000 to about 1 claim 1 ,000 claim 1 ,000.7. The amphiphilic degradable block copolymer of claim 1 , having a polydispersity from about 1.0 to about 2.0.9. The amphiphilic degradable random copolymer of claim 8 , wherein{'sub': 1', '2, 'each of Rand Ris a methyl group; and'}{'sub': 6', '18, 'R is a linear alkyl chain of a length from about Cto about C.'}10. The amphiphilic degradable random copolymer of claim 8 , wherein the ratio of hydrophilic units:lipophilic units:lipophilic units with alkyl chains ranges from about 1˜50:1˜50:1˜50 to about 50˜1:50˜1:50˜1.1112-. (canceled)13. A fibrous scaffold of made from an amphiphilic degradable copolymer of .14. The fibrous scaffold ...

Compositions and Methods for Cartilage Repair

Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.

TIMING CONTROLLED IN-SITU CROSS-LINKING OF HALYURONIC ACID DURING INJECTION

Systems and methods are disclosed for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a time release catalyst; injecting the mixture into a patient as a viscous fluid; after injection, activating the catalyst to cross-link the polymer after a predetermined period after injection into a patient; and augmenting soft tissue with the biocompatible cross-linked polymer.

COMPOSITION FOR CATHETER AND PRODUCTION METHOD THEREFOR

The present invention relates a composition for producing a foley catheter which is inserted in vivo and a method for producing the same, which the composition consists of the materials which carbon nanotube polymer (CNT Polymer) bonded a carbon nanotube and zinc oxide (ZnO) is combined with a silicon, wherein from 1.0 to 2.2 parts by weight of the said carbon nanotube polymer are combined with 100 parts by weight of silicon. 1. The composition for producing a foley catheter which is inserted in vivo which is characterized in that the composition consists of a material which a carbon nanotube polymer (CNT Polymer) bonded a carbon nanotube and zinc oxide (ZnO) is combined with a silicon ,wherein from 1.0 to 2.2 parts by weight of the said carbon nanotube polymer are combined with 100 parts by weight of silicon.2. The composition for producing a foley catheter of claim 1 , wherein the said carbon nanotube is a Multi-Walled Carbon Nanotube (MWNT).3. The composition for producing a foley catheter of claim 1 , wherein it consists of composite combining the dispersed carbon nanotube and zinc oxide (ZnO) with silicon.4. A composition for producing a foley for catheter affixed to the catheter body to be inflatable by fluid externally introduced claim 1 , it is characterized in that the said composition consists of a material which a carbon nanotube polymer (CNT Polymer) bonded a carbon nanotube and zinc oxide (ZnO) is combined with a silicon claim 1 ,wherein from 4.0 to 13.2 parts by weight of the said carbon nanotube polymer are combined with 100 parts by weight of silicon.5. The composition for producing a foley for catheter of claim 4 , wherein the said carbon nanotube is a Multi-Walled Carbon Nanotube (MWNT).6. The composition for producing a foley for catheter of claim 4 , wherein it consists of composite combining the dispersed carbon nanotube and zinc oxide (ZnO) with silicon.7. A method for manufacturing a composition for producing a foley catheter claim 4 , the ...

Nitric Oxide Releasing Pharmaceutical Compositions

The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same.

FORMATION OF SEMI-PERMEABLE POROUS ARTIFICIAL SCAB

Porous semi-permeable artificial self-attaching scab designed to protect the eroded or injured surfaces. It can be applied on any living being (including plants). The polymerized mesh of the scab is formed when applied on the injured area by a process in which the lysed cells release enzymes that catalyze the reaction. Under this protective surface, the growth of new normal cells that can breathe freely without drying up is promoted. As a result, loss of water, proteins and electrolytes can be avoided; infections can be prevented; and the use of dressing and gauze bandage can be eliminated since they harm the new skin removed. The aqueous thixotropic red-colored fluid applied by brushing or spraying was obtained as a result of the reaction occurred in the container by the combination of the following substances: azosulfamide 1% to 5%+gentian violet 0.004% to 0.007%+dexamethasone 0.001% to 0.003′%+pantothenyl alcohol 0.5% to 2%+gentamicin 0.03% to 0.06%. 1. A fluid that forms an artificial scab , comprising:1-5 weight % of azosulfamide;0.004-0.007 weight % of gentian violet;0.001-0.003 weight % of dexamethasone;0.5-2 weight % of panthenol; and0.03-0.06 weight % of gentamycin, wherein the azosulfamide, gentian violet, dexamethasone, panthenol, and gentamycin are mixed together to form an aqueous thixotropic fluid and the aqueous fluid forms an artificial scab when applied to damaged human tissue.2. The fluid that forms an artificial scab of claim 1 , further comprising a three dimensional web formed by a reaction after the application of the aqueous fluid to the damaged human tissue.3. The fluid that forms an artificial scab of claim 1 , wherein the web comprises a plurality of ionic and covalent bonds generated by the reaction after the application of the aqueous fluid to the damaged human tissue.4. The fluid that forms an artificial scab of claim 1 , wherein the artificial scab is three dimensional.5. The fluid that forms an artificial scab of claim 1 , the ...

Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods ofpreparing and using the same

Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

Vanadium Compounds as Therapeutic Adjuncts for Cartilage Injury and Repair

A method for repairing an injury of cartilage in a patient by local administration of an organovanadium agent or use of an implantable device for delivery of an organovanadium agent. Implantable devices containing an organovanadium agent and methods of making these implantable devices are also disclosed.

PLGA SCAFFOLD

Disclosed is a PLGA (poly(D,L-lactide-co-glycolide)) cell scaffold. The cell scaffold is based on a PLGA scaffold, which is an FDA-approved material with no cytotoxicity, and overcomes the problem with conventional PLGA scaffolds of poor cell adhesion. 1. A method for fabricating a cell scaffold , comprising:dissolving a PLGA (poly(D,L-lactide-co-glycolide)) substrate in an organic solvent to give a PLGA solution; andadding an effervescent agent to the PLGA solution to afford a PLGA scaffold with a porous structure.2. The method of claim 1 , further coating the PLGA scaffold with an elastin-like artificial extracellular matrix.3. The method of claim 2 , wherein the elastin-like artificial extracellular matrix is applied in an amount of 1 to 200 μg per 1 cmof a cross sectional area of the PLGA scaffold.4. The method of claim 2 , further comprising treating the elastin-like artificial extracellular matrix-coated scaffold with a cytodifferentiation agent.5. The method of claim 4 , wherein the cytodifferentiation agent comprises retinoic acid.6. The method of claim 2 , wherein the elastin-like artificial extracellular matrix comprises a compound represented by the following General Formula 1:{'br': None, 'sub': n', 'm, 'TGPG[VGRGD(VGVPG)]\u2003\u2003[General Formula 1]'}(wherein, n is an integer meeting 2≦n≦10, and m is an integer meeting 10≦m≦30)7. The method of claim 1 , wherein the organic solvent comprises at least one selected from the group consisting of tetrahydrofuran claim 1 , dimethyacetamide claim 1 , dimethylformamide claim 1 , chloroform claim 1 , dimethylsulfoxide claim 1 , butanol claim 1 , isopropanol claim 1 , isobutylalcohol claim 1 , tetrabutylalcohol claim 1 , acetic acid claim 1 , 1 claim 1 ,4-dioxane claim 1 , toluene claim 1 , ortho-xylene claim 1 , and dichloromethane.8. The method of claim 1 , wherein the PLGA solution contains the organic solvent in an amount of 4 claim 1 ,000˜5 claim 1 ,000 weight parts based on 100 weight parts of PLGA.9. The ...

Dry Spray on Hemostatic System

The invention provides for dry spray compositions comprising co-polymers comprising a core, water-soluble polymer and a peptide. 1. A dry spray composition comprising a co-block polymer.2. The dry spray composition of wherein the co-block polymer is coupled with a water soluble polymer.3. The dry spray composition of wherein the co-block polymer is a nanoparticle comprising a core claim 1 , a water soluble polymer and a peptide.4. The dry spray composition of comprising a nanoparticle claim 1 , wherein the nanoparticle comprises a water soluble polymer attached to the core at a first terminus of the water soluble polymer.5. The dry spray composition of claim 3 , wherein the peptide comprises an RGD amino acid sequence.6. The dry spray composition of further comprising a polycation.78-. (canceled)9. The dry spray composition of claim 1 , wherein the co-block polymer is poly(lactide-co-glycolide acid (PLGA) claim 1 , polylactic acid (PLA) claim 1 , polyglycolide (PGA) claim 1 , polycaprolactone (PCL) claim 1 , poly (ε-caprolactone) claim 1 , poly-L-lysine (PLL) or combinations thereof.10. The spray composition of wherein the water soluble polymer is selected from the group consisting of polyethylene glycol (PEG) claim 2 , branched PEG claim 2 , polysialic acid (PSA) claim 2 , carbohydrate claim 2 , polysaccharides claim 2 , pullulane claim 2 , chitosan claim 2 , hyaluronic acid claim 2 , chondroitin sulfate claim 2 , dermatan sulfate claim 2 , starch claim 2 , dextran claim 2 , carboxymethyl-dextran claim 2 , polyalkylene oxide (PAO) claim 2 , polyalkylene glycol (PAG) claim 2 , polypropylene glycol (PPG) claim 2 , polyoxazoline claim 2 , poly acryloylmorpholine claim 2 , polyvinyl alcohol (PVA) claim 2 , polycarboxylate claim 2 , polyvinylpyrrolidone claim 2 , polyphosphazene claim 2 , polyoxazoline claim 2 , polyethylene-co-maleic acid anhydride claim 2 , polystyrene-co-maleic acid anhydride claim 2 , poly(1-hydroxymethylethylene hydroxymethylformal) (PHF) claim 2 , ...

CROSS-LINKED FATTY ACID-BASED BIOMATERIALS

Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided. 120-. (canceled)21. A cured biomaterial comprising:fatty acids cross-linked to each other via cross-linking bridges, wherein the fatty acids are derived from fish oil;wherein the cured biomaterial is hydrolysable in vivo and a composition of the fatty acids before curing comprises at least about twenty-five percent saturated fatty acids and at least about thirty percent polyunsaturated fatty acids in terms of area % by gas chromatography fatty acid profile.22. The cured biomaterial of claim 21 , wherein the fatty acids comprise approximately 5-50% Cfatty acids in terms of area % by gas chromatography fatty acid profile.23. A medical device having a coating formed by the cured biomaterial of .24. The cured biomaterial of claim 21 , wherein the fatty acids are cross-linked to each other by ester and lactone bonds.25. The cured biomaterial of claim 21 , wherein the polyunsaturated fatty acids are primarily Cfatty acids or longer.26. The cured biomaterial of claim 21 , wherein the polyunsaturated fatty acids are primarily Cand Cfatty acids.27. The cured biomaterial of claim 21 , wherein the cross-linking bridges include a combination of peroxide bridges claim 21 , ether bridges claim 21 , and hydrocarbon bridges.28. A cured biomaterial comprising:fatty acids cross-linked to each other via cross-linking bridges, wherein the fatty acids are derived from fish oil;wherein the cured biomaterial is hydrolysable in vivo and a composition of the fatty acids before curing comprises at least five different fatty acid species ...

DESIGNS FOR TYMPANOSTOMY CONDUITS OR SUBANNULAR VENTILATION CONDUITS AND OTHER MEDICAL AND FLUIDIC CONDUITS

A system includes a device having a conduit having a proximal end having a proximal end radius, a distal end opposite the proximal end and having distal end radius, an inner surface connecting the proximal end and the distal end and forming a proximal angle at the ends, the inner surface having surface properties, and an outer surface connecting the ends; the distal end radius, the proximal end radius, the distal angle, the proximal angle, and the surface properties of the inner surface are selected to: allow entry of a first material to the distal, transport of the first material through the conduit along the inner surface toward the proximal end, and exit of the first material from the proximal end, and to resist entry of a second material into the proximal end; and the Young-Laplace pressure for the first material is less for the second material. 1104-. (canceled)105. A device comprising: a proximal end, the proximal end having a proximal end radius,', 'a distal end opposite the proximal end, the distal end having a distal end radius,', 'an inner surface connecting the proximal end and the distal end, the inner surface forming a proximal angle at the proximal end and a distal angle at the distal end, the inner surface comprising surface properties, and', 'an outer surface connecting the proximal end and the distal end;, 'a conduit comprising'} allow entry of a first material to the distal end of the conduit, allow transport of the first material through the conduit along the inner surface toward the proximal end, and allow exit of the first material from the proximal end of the conduit, and', 'resist entry of a second material into the proximal end of the conduit; and, 'wherein distal end radius, the proximal end radius, the distal angle, the proximal angle, and the surface properties of the inner surface are selected towherein the Young-Laplace pressure for the first material is less than Young-Laplace pressure for the second material.106. The device of claim ...

COATINGS FOR IMPLANTABLE DEVICES

Intraocular pressure sensors, systems, and methods of use. Implantable intraocular pressure sensing devices that are hermetically sealed and adapted to wirelessly communicate with an external device. The implantable devices can include a hermetically sealed housing, the hermetically sealed housing including therein: an antenna in electrical communication with a rechargeable power source, the rechargeable power source in electrical communication with an ASIC, and the ASIC in electrical communication with a pressure sensor. 1. An implantable device with a biocompatible coating , comprising:an implantable device having an outer surface; anda coating disposed on the outer surface of the implantable device, an inner layer disposed on the implantable device outer surface, and an exterior layer exposed to the ambient environment,', 'wherein the inner layer has an inner cross link density, and the exterior layer has an exterior cross link density that is lower than an inner layer cross link density., 'the coating comprising'}2. The implantable device of claim 1 , wherein the exterior layer has an exterior refractive index and the inner layer has an inner refractive index different than the exterior refractive index.3. The implantable device of claim 2 , wherein the exterior refractive index is less than the inner refractive index.4. The implantable device of claim 3 , wherein the exterior refractive index is between 1.39 and 1.44.5. The implantable device of claim 3 , wherein the inner refractive index is between 1.44 and 1.50.6. The implantable device of claim 1 , wherein at least one of the outer layer and the inner layer has a gradient refractive index claim 1 , with the refractive index being greater at an innermost location of the layer than at an outermost location of the layer.7. The implantable device of claim 1 , wherein the exterior layer has a water content that is higher than an inner layer water content.8. The implantable device of claim 1 , wherein the inner ...

Implants having a drug load of an oxysterol and methods of use

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.

MODULAR BIORESORBABLE OR BIOMEDICAL, BIOLOGICALLY ACTIVE SUPRAMOLECULAR MATERIALS

The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or biomedical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and bioresorption properties). The supramolecular bioresorbable or biomedical material is especially suitable for biomedical applications such as controlled release of drugs, materials for tissue-engineering, materials for the manufacture of a prosthesis or an implant, medical imaging technologies. 2. The implant or coating according to claim 1 , wherein the polymer is derived from the group consisting of polyesters claim 1 , polycarbonates claim 1 , and copolymers from these polymers.3. The implant or coating according to claim 1 , wherein the polymer is derived from the group consisting of polycaprolactone claim 1 , polylactide claim 1 , polyglycolide claim 1 , poly(trimethylene) carbonate claim 1 , poly(1 claim 1 ,6-hexanediol) carbonate claim 1 , and copolymers from these polymers.4. The implant or coating according to claim 1 , wherein the biologically active compound is selected from the group consisting of antimicrobial agents claim 1 , anti-viral agents claim 1 , anti-tumor agents claim 1 , antithrombogenic agents claim 1 , hormones claim 1 , immunogenic agents claim 1 , growth factors claim 1 , dyes claim 1 , fluorescent dyes claim 1 , contrast agents claim 1 , nucleic acids claim 1 , lipids claim 1 , lipopolysaccharides claim 1 , saccharides claim 1 , polysaccharides claim 1 , vitamins claim 1 , peptides claim 1 , oligopeptides claim 1 , proteins claim 1 , apatite claim 1 , hydroxyapatite claim 1 , anaesthetics claim 1 , muscle relaxants claim 1 , and corticosteroids.5. The implant or coating according to claim 1 , wherein the implant or coating has a highly porous structure.6. The implant or ...

POLYSACCHARIDE COATING

The invention relates to a method for coating the balloon of a balloon catheter, wherein the surface of the balloon is wetted at least partially with a first solution containing a polysaccharide and the part of the surface of the balloon wetted with the first solution is wetted with a second solution containing an active agent. In this way, the balloon is provided with an active agent layer which is effectively applied to the inner wall of the vessel when the balloon is inflated and moreover results in a delayed long-lasting release of the active agent. 1. Method for coating the balloon of a balloon catheter , wherein the surface of the balloon is at least partially wetted with a first solution containing a polysaccharide , characterized in that the part of the surface of the balloon wetted with the first solution is wetted with at least one second solution containing an active substance.2. Method according to claim 1 , characterized in that the part of the surface of the balloon wetted with the active substance is again wetted with a further liquid containing water and/or at least one alcohol.3. Method according to claim 2 , characterized in that the water and/or at least one alcohol containing liquid contains one alcohol and/or one ketone.4. Method according to claim 2 , characterized in that the concentration of the alcohol and/or ketone in the liquid ranges between 10 and 70% (v/v) claim 2 , preferably between 30 and 65% (v/v) claim 2 , further preferred between 50 and 60% (v/v).5. Method according to claim 3 , characterized in that the liquid contains ethanol claim 3 , methanol claim 3 , acetone and/or isopropanol.6. Method according to claim 1 , characterized in that the first and/or the second solution contains one or several alcohols.7. Method according to claim 6 , characterized in that the concentration of the alcohol in water in the first and/or second solution ranges between 10 and 70% (v/v) claim 6 , preferably between 30 and 65% (v/v) claim 6 , further ...

EMBOLIC MATERIAL AND METHOD FOR PRODUCING SAME

An embolic material contains at least one type of polymer and a liposoluble contrast medium. A method for producing an embolic material includes extruding a raw material that is in a molten state into a solvent, and cooling the raw material so as to solidify the raw material. The raw material contains a polymer and a liposoluble contrast medium. 1. An embolic material comprising:at least one type of polymer: anda liposoluble contrast medium.2. The embolic material according to claim 1 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.3. The embolic material according to claim 1 ,wherein the polymer is biodegradable.4. The embolic material according to claim 1 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate.5. A method for producing an embolic material claim 1 , the method comprising:extruding a raw material containing at least one type of polymer and a liposoluble contrast medium into a solvent, the raw material being in a molten state; andcooling the raw material so as to solidify the raw material.6. The method for producing an embolic material according to claim 5 ,wherein the raw material extruded into the solvent forms spherical shapes.7. The method for producing an embolic material according to claim 5 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.8. The method for producing an embolic material according to claim 5 ,wherein the polymer is biodegradable.9. The method for producing an embolic material according to claim 5 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate. This international application claims the ...

IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITUS

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. 124-. (canceled)25. A method of treatment of a human patient , comprising: i) a first layer comprising mometasone furoate and a biodegradable polymer material and', 'ii) a therapeutic-agent-free polymer topcoat layer, said topcoat layer positioned on said first layer; and, 'a) providing a scaffold comprising'}b) delivering said scaffold to the middle meatus under conditions where the scaffold delivers said mometasone furoate from the middle meatus to a sinus cavity of a human patient, said sinus cavity selected from the group consisting of the maxillary, frontal, sphenoid and ethmoid sinuses.26. The method of claim 25 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.27. The method of claim 25 , wherein said patient has failed medical management based on the administration of oral steroids.28. The method of claim 25 , wherein said patient has failed medical management based on the administration of topical steroids.29. The method of claim 25 , wherein said treatment is a postoperative treatment following functional endoscopic sinus surgery.30. A method of treatment of a subject with a sinus condition claim 25 , comprising: i) a first layer comprising mometasone furoate and a polymer material and', 'ii) a polymer topcoat layer, said topcoat layer positioned on said first layer; and, 'a) providing a scaffold comprisingb) delivering said scaffold to the middle meatus under conditions where the scaffold delivers said mometasone furoate from the middle meatus to a sinus cavity of a subject with a sinus condition, said sinus cavity selected from the group consisting of the maxillary, frontal, sphenoid and ethmoid sinuses.31. The method of claim 30 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.32. The method of claim 30 , wherein said subject is a human patient that has failed medical ...

SUSTAINED-RELEASE DRUG CARRIER COMPOSITION

The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof. 174-. (canceled)75. Tri calcium phosphate (TCP) particles having their surface coated fully or partially with a biocompatible matrix composition , the matrix composition comprising:a. a biodegradable polymer;b. a first lipid comprising a sterol;c. a second lipid comprising at least one phospholipid having hydrocarbon chains of at least 14 carbons; andd. a pharmaceutical active agent;wherein the matrix composition is lipid saturated, and when maintained in an aqueous environment provides sustained release of the pharmaceutical active agent.76. The coated particles of claim 75 , wherein said phospholipid is a phosphatidylcholine having fatty acid moieties having at least 14 carbons.77. The coated particles of wherein the biodegradable polymer is a biodegradable polyester selected from the group consisting of PLA (polylactic acid) claim 75 , PGA (poly glycolic acid) and PLGA (Poly (lactic co glycolic acid).78. The coated particles of wherein the pharmaceutical active agent is selected from an antibiotic claim 75 , an antifungal claim 75 , a non-steroidal anti-inflammatory drug claim 75 , a steroid claim 75 , an anti-cancer agent claim 75 , an osteogenic factor and a bone resorption inhibitor.79. The coated particles of claim 78 , wherein said pharmaceutical active agent is an antibiotic or antifungal.80. The coated particles of claim 79 , wherein the antibiotic is doxycycline or doxycycline hyclate.81. The coated particles of claim 78 , wherein said pharmaceutical active agent is an anticancer agent.82. The coated particles of claim 81 , wherein the anticancer agent is docetaxel.83. The ...

DRUG ELUTING COMPOSITE

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials. 1. A therapeutic-releasing device comprising: a first coated film;', 'a first therapeutic agent incorporated within the first coated film;', 'a first capping layer that substantially covers all of the first coated film and is impermeable to the first therapeutic agent; and', 'a first opening in the first capping layer; and, 'a first therapeutic-releasing construction including a second coated film;', 'a second therapeutic agent incorporated within the second coated film;', 'a second capping layer that substantially covers all of the second coated film and is impermeable to the second therapeutic agent; and', 'a second opening in the second capping layer,, 'a second therapeutic-releasing construction includingwherein the first therapeutic-releasing construction is stacked inside the second therapeutic-releasing construction.2. The therapeutic-releasing device of claim 1 , wherein the first therapeutic-releasing construction further includes a first elution pathway for the first therapeutic agent through the first coated film that exits the first coated film at the first opening.3. The therapeutic-releasing device of claim 2 , wherein the second therapeutic-releasing construction further includes a second elution pathway for the second therapeutic agent through the second coated film that exits the second coated film at the second opening.4. The therapeutic-releasing device of claim 3 , wherein the first coated film is a polymeric material comprising one or more polymeric barriers that are substantially impermeable to the first therapeutic agent and define the first elution pathway.5. The therapeutic-releasing device of claim 4 , wherein the second coated film is a polymeric material comprising ...

PLASMA-ENRICHED HYDROXYAPATITE-BASED FILLER MATERIAL AND METHOD OF FILLING BONE GAPS WITH THE SAME

Plasma-enriched hydroxyapatite-based fillers and methods of filling bone gaps in oral surgery, orthopedic procedures, and cosmetic surgery are disclosed. The fillers contain a substance comprising an anticoagulant antidote, a substance comprising hydroxyapatite, and blood or plasma. The blood may be either autologous or allogeneic. The fillers have a dough-like consistency and can be manipulated easily by a surgeon. 1. A bone filler , comprising:a first substance comprising an anticoagulant antidote;a second substance comprising hydroxyapatite; andblood or plasma;wherein the bone filler is free of bone tissue.2. The bone filler of claim 1 , wherein the bone filler further comprises an anticoagulant.3. The bone filler of claim 2 , wherein the anticoagulant is a heparin salt claim 2 , an EDTA salt claim 2 , a citrate salt claim 2 , or a mixture thereof.4. The bone filler of claim 1 , wherein the first substance includes one or more excipients selected from the group consisting of thickeners claim 1 , diluents claim 1 , pH buffers claim 1 , acids and bases claim 1 , adhesives claim 1 , polymeric compounds claim 1 , and fluorescing compounds.5. The bone filler of claim 1 , wherein the anticoagulant antidote is selected from the group consisting of protamine sulfate claim 1 , salts of protamine sulfate claim 1 , calcium chloride claim 1 , soluble calcium or lithium salts claim 1 , thrombin claim 1 , and mixtures thereof.6. The bone filler of claim 1 , wherein the blood or plasma is autologous.7. The bone filler of claim 6 , wherein the anticoagulant antidote is selected from the group consisting of protamine sulfate claim 6 , salts of protamine sulfate claim 6 , calcium chloride claim 6 , soluble calcium or lithium salt claim 6 , thrombin claim 6 , and mixtures thereof.8. A method of filling a bone gap comprising:mixing together a substance comprising an anticoagulant antidote, a substance comprising hydroxyapatite, and blood or plasma to form a bone filler; andapplying ...

NOVEL ENDOTRACHEAL TUBE FOR THE REDUCTION OF INTUBATION-RELATED COMPLICATION IN NEONATES AND BABIES

This disclosure relates to medical devices incorporating one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the medical devices to provide effective antimicrobial, anti-inflammatory, and/or tissue-healing properties. A medical device includes a component formed from a polymeric material. One or more CSA compounds are mixed with the polymeric material so that the one or more CSA compounds are incorporated into the structure of the medical device as formed from the polymeric material. A medical device can additionally or alternatively include a lubricious coating containing one or more CSA compounds. 1. An implantable medical device , the implantable medical device comprising:a structural component formed at least in part from a polymeric material; andone or more CSA compounds, the one or more CSA compounds being incorporated into the polymeric material of the structural component so as to be distributed throughout the structural component.2. The medical device of claim 1 , wherein the medical device is a catheter claim 1 , endotracheal tube claim 1 , intravenous line claim 1 , feeder tube claim 1 , drain claim 1 , prosthesis component claim 1 , peristaltic pump component claim 1 , tympsanostomy tube claim 1 , or tracheostomy tube.3. The medical device of claim 1 , wherein the polymeric material is extrudable.4. The medical device of claim 1 , wherein the polymeric material is a thermoset polymer.5. The medical device of claim 1 , wherein the polymeric material comprises silicone.6. The medical device of claim 1 , further comprising a coating disposed on a surface of the structural component of the medical device claim 1 , the coating including one or more CSA compounds incorporated therein.7. The medical device of claim 6 , wherein the coating comprises a hydrogel.8. The medical device of claim 6 , wherein the coating is configured as a lubricious coating reducing the coefficient of friction of the surface of the medical device upon ...

Gene Delivery Stent Using Titanium Oxide Thin Film Coating and Method for Fabricating the Same

The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells. Accordingly, late thrombosis and metal allergy may be reduced, and vascular restenosis in the stent region may be prevented, thereby making it possible to increase treatment effects of the bare metal stent. 1. A gene delivery stent using titanium oxide thin film coating , the gene delivery stent comprising:{'sub': 2', '2-x', 'x, 'a titanium oxide thin film obtained by coating a surface of a metal stent with TiO, TiON(0.001≦x≦1), or a mixture thereof and modifying the coated surface to introduce a hydroxyl group;'}a drug layer containing a drug having a functional group bound to a hydroxyl group of the titanium oxide thin film to thereby be adhered onto the titanium oxide thin film; andan oligonucleotide layer containing oligonucleotide bound to the drug to thereby be adhered onto the drug layer.2. The gene delivery stent of claim 1 , wherein the titanium oxide thin film is a titanium dioxide (TiO) thin film or a nitrogen-doped titanium oxide (TiON(0.001≦x≦51)) thin film.3. The gene delivery stent of claim 1 , wherein the drug is at least one of abciximab claim 1 , alpha lipoic acid (ALA) claim 1 , and heparin.4. The gene delivery stent of claim 1 , wherein the oligonucleotide is selected from a group consisting of gDNA claim 1 , cDNA claim 1 , pDNA claim 1 , mRNA claim 1 , tRNA claim 1 , rRNA claim 1 , siRNA claim 1 , miRNA claim 1 , and antisense-oligonucleotide. The present application is a division of U.S. patent application Ser. No. 13/993,896, filed Oct. 8, 2013, which is the United States National Phase of International Patent Application No. PCT/KR2011/009298, filed Dec. 2, ...

Multi-layer biomaterial for tissue regeneration and wound healing

The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects.

POLYMER PARTICLES

Described are polymers and methods of forming and using same. 1. A particle including:at least one monomer amenable to polymerization;at least one crosslinker; andat least one pharmaceutical agent chemically bonded to the particle with a hydrolytically degradable linkage.2. The particle of claim 1 , wherein the particle is biostable.3. The particle of claim 1 , wherein the crosslinker is biostable.4. The particle of claim 1 , wherein the particle is biodegradable.5. The particle of claim 1 , wherein the at least one monomer amenable to polymerization includes glycerol monomethacrylate.6. The particle of claim 1 , wherein the at least one monomer amenable to polymerization includes dimethyl acrylamide.7. The particle of claim 1 , wherein the crosslinker is biodegradable.19. A method of forming a particle of comprising:reacting a prepolymer solution including the dimethyl acrylamide, the glycerol monomethacrylate, the at least one crosslinker, and the at least one pharmaceutical agent, andforming the particle.20. A method of treating a vessel comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to the vessel a plurality of particles according to .'} This application claims the benefit of U.S. provisional patent application No. 62/401,091, filed Sep. 28, 2016 and U.S. provisional patent application No. 62/428,990, filed Dec. 1, 2016, the entire disclosures each of which is incorporated herein by reference.Described herein are polymeric particles configured for intravascular delivery of pharmaceutical agents, e.g., to a diseased site. Preparation of these polymer particles is also described.Described herein are polymer particles. In some embodiments, the particles are hydrogel particles. These particles can be configured to deliver pharmaceutical agents and can also be used for embolization. In some embodiments, the polymers used herein can include at least one monomer amenable to polymerization, at least one crosslinker, and at least one ...

Polymer particles

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

MODULAR POLYMER PLATFORM FOR THE TREATMENT OF CANCER

The invention provides a novel polymer platform to deliver a desired combination of therapeutic agents to a site in need thereof for the treatment of cancer. In certain embodiments the platform is a modular polymer platform that allows for customization based upon the tumor of the subject to be treated. 1. A modular polymer platform comprising two or more therapeutic agents releasable from a polymeric substrate , wherein at least one of the two or more therapeutic agents is an anti-tumor agent.2. The modular polymer platform of claim 1 , wherein at least one of the two or more therapeutic agents is an immunomodulator.3. The modular polymer platform of wherein the immunomodulator is selected from the group consisting of CCL21 claim 2 , IL-2 claim 2 , IL-6 claim 2 , IL-8 claim 2 , IL-7 claim 2 , IL-10 claim 2 , IL-12 claim 2 , interferon claim 2 , G-CSF claim 2 , imiquimod claim 2 , CCL3 claim 2 , CCL26 claim 2 , CXCL7 claim 2 , oligodeoxynucleotides claim 2 , and glucan.4. The modular polymer platform of claim 2 , wherein the substrate comprises a cell genetically modified to express the immunomodulator.5. The modular polymer platform of claim 1 , wherein the anti-tumor agent is a chemotherapeutic agent.6. The modular polymer platform of claim 1 , wherein the polymeric substrate comprises two or more layers claim 1 , and wherein each layer has associated therewith at least one therapeutic agent.7. The modular polymer platform of claim 6 , wherein a first layer is a hydrogel.8. The modular polymer platform of claim 6 , wherein a second layer is a polymer matrix.9. The modular polymer platform of claim 8 , wherein the polymer matrix comprises PCL and PLCL.10. The modular polymer platform of claim 6 , wherein the first layer and second layer release the at least one therapeutic agent comprised therein at different rates.11. The modular polymer platform of claim 1 , wherein polymeric substrate comprises an impermeable backing layer.12. The modular polymer platform of ...

NANOMATERIALS FOR THE INTEGRATION OF SOFT INTO HARD TISSUE

Nanocomposite materials are provided for attaching soft tissue to hard tissue of a mammalian subject. The materials include a biodegradable polymer network suffused with mineral nanoparticles. The nanocomposite materials have a surface structure that promotes the infiltration, adhesion and proliferation of cells such as osteoblasts and fibroblasts, and are useful to reconstruct enthesis tissue, such as a tendon bone insertion. Devices containing the nanocomposites and methods for implantation of the devices at a tendon-bone interface or ligament-bone interface are provided for reconstructive surgery. 1. A composite material comprising a biodegradable polymer matrix , a plurality of MgO nanoparticles embedded in the matrix , and a plurality of hydroxyapatite nanoparticles embedded in the matrix.26-. (canceled)7. The material of claim 1 , wherein the hydroxyapatite nanoparticles are present at about 10 wt % to about 60 wt %.8. The material of comprising about 10 wt % MgO nanoparticles.9. The material of comprising about 10 wt % hydroxyapatite nanoparticles.10. The material of claim 1 , further comprising a plurality of adsorbed cells.11. (canceled)12. The material of claim 1 , wherein the MgO nanoparticles are present in a gradient of concentration through the material.13. The material of claim 1 , wherein the hydroxyapatite nanoparticles are present in a gradient of concentration through the material.14. The material of claim 1 , wherein a surface of the material promotes cell adhesion.15. (canceled)16. The material of claim 1 , wherein a surface of the material promotes cell proliferation.17. (canceled)18. The material of claim 1 , further comprising one or more growth factors.19. The material of claim 18 , wherein the material comprises dexamethasone.20. An enthesis regeneration device comprising the composite material of formed into a ring-shaped structure and having an inner surface and an outer surface claim 1 , the inner surface configured to surround a tendon ...

NASAL DRESSINGS AND STENTS

Disclosed are nasal dressings and nasal stents comprising a collagen foam. Also disclosed are methods of making and using such nasal dressings and nasal stents. In an embodiment, a nasal dressing or nasal stent is formed by a method comprising the steps of: forming an aqueous mixture of from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers, both based on the total solids content of the aqueous mixture, placing the aqueous mixture into a mold, freeze-drying the aqueous mixture while in the mold, thereby forming a collagen foam, and cross-linking the collagen foam. 1. A nasal dressing or nasal stent for treating a wound or inflammation in the nasal cavity of a patient comprising a collagen foam comprising cross-linked acid-soluble collagen and collagen fibers , wherein the nasal dressing or stent comprises the shape of a central hub having a plurality of radiating arms.2. The nasal dressing or nasal stent according to claim 1 , wherein the collagen foam comprises from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers.3. The nasal dressing or nasal stent according to claim 1 , wherein the collagen foam is formed by lyophilizing an aqueous mixture of from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers claim 1 , both based on the total solids content of the aqueous mixture claim 1 , followed by cross-linking.4. The nasal dressing or stent according to claim 1 , wherein the nasal dressing or nasal stent is formed by a method comprising the steps of:a. forming an aqueous mixture of from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers, both based on the total solids content of the aqueous mixture,b. placing the aqueous mixture into a mold,c. freeze-drying the aqueous mixture while in the mold, thereby forming a collagen foam, andd. cross-linking the collagen foam.5. The nasal dressing or stent according to claim 1 , wherein the nasal dressing or ...

DELIVERY OF HIGHLY LIPOPHILIC AGENTS VIA MEDICAL DEVICES

An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen. 1162.-. (canceled)163. A system for delivering a lipophilic agent to a subject , comprising:a medical device;{'sup': '−1', 'a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficient of said first lipophilic agent is at least 5,000 (ug/mL), wherein said first lipophilic agent is attached directly to, or present as a coating or part of a coating on said medical device, wherein said first lipophilic agent/medical device is configured so that it can be placed adjacent to said body lumen; and'}wherein the medical device is capable of delivering a therapeutically effective amount of said first lipophilic agent to a desired area within the subject.164. The system according to claim 163 , further comprises at least one pharmaceutically acceptable carrier or excipient claim 163 , wherein said pharmaceutically acceptable carrier or excipient is attached directly to claim 163 , or present as a coating or part of a coating on medical device.165. The system according to claim 164 , wherein said pharmaceutically acceptable carrier or excipient is a polymer.166. The system according to claim 163 , wherein said ...

COMPOSITIONS AND METHODS FOR ALTERING THE RATE OF HYDROLYSIS OF CURED OIL-BASED MATERIALS

Disclosed herein is the correlation of chemical properties of oils with the physical properties of a resulting cured oil composition. Also disclosed are biocompatible materials and coatings for medical devices prepared using enriched oils and methods for enhancing or modifying the physical and chemical characteristics of cured oils by enriching such oils with fatty acid alkyl esters. Methods of tailoring the properties of biocompatible materials and coatings to deliver one or more therapeutic agents are also provided. 1112-. (canceled)113. A method of increasing in vivo hydrolysis rate of a cured oil coating having cross-linked fatty acids , wherein the method comprises the steps of:enriching one or more primary oils with one or more secondary oils comprising fatty acid alkyl esters to form an enriched oil composition; andexposing the enriched oil composition to curing conditions to form a first cured oil coating that has increased polarity and an increased in vivo hydrolysis rate relative to a hypothetical second cured oil coating that corresponds to a non-enriched oil composition that is subjected to the curing conditions but has not been enriched with the one or more secondary oils.114. The method of claim 113 , wherein the secondary oil is fish oil.115. The method of claim 113 , wherein the secondary oil is plant oil.116. The method of claim 113 , wherein the cured oil coating forms a coating on a medical device.117. The method of claim 113 , wherein the fatty acid alkyl esters are selected from the group consisting of linear C1-C6 alkyl esters and branched C1-C6 alkyl esters.118. The method of claim 113 , wherein the enriched oil composition comprises between about 25% and about 75% w/w fatty acid alkyl esters.119. The method of claim 113 , wherein the fatty acid alkyl esters comprise an ethyl ester of eicosapentaenoic acid (EPA).120. The method of claim 113 , wherein the fatty acid alkyl esters comprise an ethyl ester of docosahexaenoic acid (DHA).121. The ...

Implantable Scaffolds for Treatment of Sinusitus

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. 124-. (canceled)25. A method of treatment of a human patient with chronic rhinosinusitis , comprising: i) a therapeutic-agent-containing layer comprising mometasone furoate and a biodegradable polymer material and', 'ii) a therapeutic-agent-free polymer topcoat layer, said topcoat layer positioned on said therapeutic-agent-containing layer so as to slow the release of the mometasone furoate;, 'a) providing a scaffold comprising'}b) delivering said scaffold to the middle meatus under conditions where the scaffold conforms to the middle turbinate and delivers said mometasone furoate from the middle meatus to a sinus cavity of a human patient with chronic rhinosinusitis.26. The method of claim 25 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.27. The method of claim 25 , wherein said patient has failed medical management based on the administration of oral steroids.28. The method of claim 25 , wherein said patient has failed medical management based on the administration of topical steroids.29. A method of treatment of a human patient with chronic rhinosinusitis claim 25 , comprising: i) a therapeutic-agent-containing layer comprising mometasone furoate and a biodegradable polymer material and', 'ii) a polymer topcoat layer, said topcoat layer positioned on said therapeutic-agent-containing layer so as to slow the release of the mometasone furoate;, 'a) providing a scaffold comprising'}b) delivering said scaffold to the middle meatus under conditions where the scaffold conforms to the middle turbinate and delivers said mometasone furoate from the middle meatus to a sinus cavity of a human patient with chronic rhinosinusitis.30. The method of claim 29 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.31. The method of claim 29 , wherein said patient has failed medical management based on the ...

IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. More specifically, a drug-eluting scaffold is implanted in the middle meatus to treat chronic sinusitis for weeks to months. 139-. (canceled)40. A method of treatment , comprising delivering an expandable scaffold comprising a therapeutic agent into the middle meatus of a human patient , wherein the expandable scaffold is one for which , when submersed in a pH 7.4 PBS buffer solution containing 2 wt % SDS at 37° C. under gentle shaking on a rotary shaker and the buffer solution is removed completely on a weekly basis as a sample for therapeutic agent quantification and replaced with fresh buffer ,(a) a quantity of therapeutic agent released in each sample, relative to a total amount of therapeutic agent originally in the scaffold, ranges from 1% to 10%, beginning with the second week sample and extending up to the twelfth week sample, or{'sup': '2', '(b) a quantity of therapeutic agent released per unit scaffold area in each sample, beginning with the second week sample and extending up to the twelfth week sample, ranges from 0.05 to 4 μg/mm/week, where scaffold area is equal to πDL, where D is the manufactured diameter of the scaffold and L is the manufactured length of the scaffold, or'}(c) both (a) and (b).41. The method of claim 40 , wherein the expandable scaffold is delivered to the native middle meatus using a 2 to 4 mm catheter. This application is a continuation in part of U.S. Ser. No. 15/197,686 entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS and filed Jun. 29, 2016, which claims the benefit of U.S. Provisional Application No. 62/186,030 entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS and filed Jun. 29, 2015, U.S. Provisional Application No. 62/289,982 entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS and filed Feb. 2, 2016, and U.S. Provisional Application No. 62/332,134 entitled IMPLANTABLE SCAFFOLDS FOR ...

STENTS FOR THE RELEASE OF ACTIVE PRINCIPLES

In an embodiment, a stent (S) implantable in a vessel of a patient, comprises recesses () loaded with an active principle with anti-inflammatory activity () and an active principle with anti-proliferative activity (). The active principle with anti-inflammatory activity () and the active principle with anti-proliferative activity () have respective formulations, whereby the active principle with anti-inflammatory activity ()and the active principle with anti-proliferative activity () have respective release kinetics as a function of said formulations, with the release of the active principle with anti-inflammatory activity () being faster than the release of the active principle with anti-proliferative activity (). 12001020102010201020. A stent (S) for implantation in a vessel of a patient , the stent including recesses () loaded with an active principle with anti-inflammatory activity () and an active principle with anti-proliferative activity () , said active principle with anti-inflammatory activity () and said active principle with anti-proliferative activity () having respective formulations , whereby said active principle with anti-inflammatory activity () and said active principle with anti-proliferative activity () have respective release kinetics as a function of said formulations , wherein the release of the active principle with anti-inflammatory activity () is faster than the release of the active principle with anti-proliferative activity ().210201020. The stent of claim 1 , wherein said respective formulations of said active principle with anti-inflammatory activity () and said active principle with anti-proliferative activity () include excipients with different melting temperatures for formulating said active principle with anti-inflammatory activity () and for formulating said active principle with anti-proliferative activity ().31020. The stent of claim 2 , wherein said respective formulations of said active principle with anti-inflammatory ...

BALLOON ANGIOPLASTY CATHETER COATING TO ENCOURAGE VESSEL REPAIR AND FURTHER REDUCE RESTENOSIS

A method for treating a target vascular portion of a subject including: providing an angioplasty balloon system including a balloon carrying a first therapeutic agent and a second therapeutic agent on a surface of the balloon, wherein the first therapeutic agent is an anti-proliferative or anti-mitotic agent and the second therapeutic agent is a drug that aids in vascular healing on a surface of the balloon; positioning the balloon proximate the target vascular portion; expanding the balloon to engage the target vascular portion; thereby delivering at least a portion of the active agent to the target vascular portion; and withdrawing the balloon from the subject. 1. An angioplasty balloon catheter comprising:a catheter;an inflatable balloon coupled to the catheter, wherein the inflatable balloon comprises a balloon surface; anda coating on at least a portion of the balloon surface, wherein the coating comprises a first therapeutic agent and a second therapeutic agent, wherein the first therapeutic agent is an anti-proliferative or anti-mitotic agent and the second therapeutic agent is a drug that aids in vascular healing.2. The angioplasty balloon catheter of claim 1 , wherein the first therapeutic agent is a restenosis inhibitor.3. The angioplasty balloon catheter of claim 1 , wherein the first therapeutic agent is selected from the group consisting of paclitaxel claim 1 , docetaxel claim 1 , abraxane claim 1 , sirolimus claim 1 , everolimus claim 1 , zotarolimus claim 1 , and tranilast.4. The angioplasty balloon catheter of claim 1 , wherein the first therapeutic agent is paclitaxel.5. The angioplasty balloon catheter of claim 1 , wherein the second therapeutic agent is selected from pro-resolving mediators.6. The angioplasty balloon catheter of claim 1 , wherein the second therapeutic agent is selected from the group consisting of derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids and their therapeutically stable analogs.7. ...

Coatings and methods for infection-resistant medical devices

Disclosed herein are compositions useful for coating medical devices which have antimicrobial (anti-infective) qualities and which are simple to manufacture and cost-effective, and therefore suitable for global use, including in developing countries with economic constraints, and in a cost-conscious healthcare environment. In one embodiment, disclosed are formulations that include chlorhexidine (CHX), curcumin (CUR), for example, curcumin C3 complex, and a silver (Ag) salt. Other embodiments pertain to compositions that include CHX, Ag and a lubricating agent. The antimicrobial coatings made according to embodiments of the invention are easier to produce, have superior efficacy and devices coated with this composition show initial release of antimicrobials and prolonged prevention of bacterial adherence, compared to currently available alternatives, to significantly reduce device-related infection especially catheter associated urinary tract infection. 1. A composition for providing an antibacterial coating , which comprises:(a) a solvent;(b) a chlorhexidine compound selected from chlorhexidine base and chlorhexidine salt;(c) a silver compound selected from elemental silver and silver salt;(d) a curcumin compound, and an optional lubricity enhancing agent(e) a pH adjusting compound selected from an acid; and(f) a biomedial polymer.2. The composition of claim 1 , wherein the solvent is tetrahydrofuran (THF) or THF and an alkanol.3. The composition of claim 2 , wherein the alkanol is selected from methanol claim 2 , ethanol claim 2 , propanol claim 2 , isopropanol claim 2 , 1 claim 2 ,3-propanediol claim 2 , 2-methyl-2 propanol claim 2 , hexanol claim 2 , or any combination thereof.4. The composition of claim 2 , wherein the solvent is THF.5. The composition of claim 2 , wherein the solvent is a combination of THF and methanol.6. The composition of claim 1 , wherein the chlorhexidine compound is chlorhexidine base.7. The composition of claim 1 , wherein the silver ...

Wound management system and methods of using

A wound management system can comprise a surgically acceptable adhesive disposed over a wound and a surgically acceptable film repositionably disposed over the surgically acceptable adhesive, and methods of managing a wound involving the same.

POLYMER PARTICLES

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents. 2. The embolic system of claim 1 , wherein the polymer particles have a diameter between about 40 μm and about 1 claim 1 ,200 μm.3. The embolic system of claim 1 , wherein the polymer particles have a diameter between about 75 μm and about 1 claim 1 ,200 μm.4. The embolic system of claim 1 , wherein the at least one functional group is acrylate claim 1 , acrylamide claim 1 , methacrylate claim 1 , or methacrylamide.5. The embolic system of claim 1 , wherein the at least one monomer includes an ionizable functional group.6. The embolic system of claim 5 , wherein the ionizable functional group is basic.7. The embolic system of claim 5 , wherein the ionizable functional group is acidic.8. The embolic system of claim 1 , wherein the polymer particles include a second crosslinker including a second linkage selected from an ester claim 1 , a thioester claim 1 , a carbonate claim 1 , a peptide cleavable by matrix metalloproteinases claim 1 , a peptide cleavable by matrix collagenases claim 1 , a peptide cleavable by matrix elastases claim 1 , and a peptide cleavable by matrix cathepsins.9. The embolic system of claim 1 , wherein the polymer particles are biodegradable.10. The embolic system of claim 1 , wherein the polymer particles are substantially degraded within about 1 months of implantation.11. The embolic system of claim 1 , wherein the at least one monomer is dimethylacrylamide.12. The embolic system of claim 1 , wherein the at least one monomer is acrylamide.14. The method of claim 13 , wherein the polymer particles have a diameter between about 40 μm and about 1 claim 13 ,200 μm.15. The method of claim 13 , further comprising:mixing a radiopaque contrast agent with the polymer particles.16. The method of claim 13 , wherein the delivering is through a catheter claim 13 , a microcatheter claim 13 , or a ...

Implant coating material for enhancing a bioactivity and osseointegration of implant surface, and the method for manufacturing and storing the same

A method for forming a coating film of a material for enhancing bioactivity, such as a water-soluble vitamin, on a surface of a dental implant, and a dental implant produced by the method, in order to overcome the limitations in improving osseointegration capability, which result from existing physical surface treatments, such as RBM and SLA surface treatments. The methods enable the SLA-pretreated implant surface to have blood affinity and an enhanced bioactive function, thereby providing a method for producing a dental implant which has excellent biocompatibility and high osseointegration capability after the implant procedure and thus has enhanced bioactivity, and a dental implant produced by the method. The surface of the dental implant, from which organic pollutants have been removed, are coated with a bioactive material, thereby enhancing blood affinity and bioactivity of the implant and thus improving initial osseointegration capability of the implant.

LYOPHILIZED MOLDABLE IMPLANTS CONTAINING AN OXYSTEROL

Provided is a lyophilized implant configured to fit at or near a bone defect to promote bone growth, the lyophilized implant containing a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant, mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant, and an oxysterol in an amount of about 5 wt. % to about 90 wt. % of the implant. Methods of making and using the implant are further provided. 1. A lyophilized implant configured to fit at or near a bone defect to promote bone growth , the lyophilized implant comprising a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant , mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant , and an oxysterol in an amount of about 0.01 wt. % to about 90 wt. % of the implant.2. A lyophilized implant of claim 1 , wherein the oxysterol comprises (3S claim 1 ,5S claim 1 ,6S claim 1 ,8R claim 1 ,9S claim 1 ,10R claim 1 , 13S claim 1 ,14S claim 1 ,17S) 17-((S)-2-hydroxyoctan-2-yl)-10 claim 1 ,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3 claim 1 ,6-diol (Oxy133) claim 1 , Oxy153 or hydrates claim 1 , solvates claim 1 , amorphous forms claim 1 , or pharmaceutically acceptable salts thereof.3. A lyophilized implant of claim 1 , wherein (i) the biodegradable polymer is crosslinked and forms a lyophilized implantable matrix or (ii) the biodegradable polymer is not crosslinked.4. A lyophilized implant of claim 3 , wherein the biodegradable polymer comprises porcine-derived collagen claim 3 , human-derived collagen claim 3 , bovine-derived collagen claim 3 , piscine-derived collagen claim 3 , ovine-derived collagen claim 3 , recombinant collagen claim 3 , gelatin claim 3 , or combinations thereof.5. A lyophilized implant of claim 1 , wherein the mineral particles comprise (i) bone powder claim 1 , demineralized bone powder claim 1 , porous calcium phosphate ceramics claim 1 , hydroxyapatite claim 1 , ...

ABSORBENT ARTICLE

An object of the disclosure is to provide an absorbent article without a sticky feel on the top sheet and with a smooth top sheet, even after highly viscous menstrual blood has been absorbed. An absorbent article comprising a liquid-permeable top sheet, an absorbent body, a liquid-impermeable back sheet, and a second sheet between the liquid-permeable top sheet and the absorbent body, wherein the top sheet and the second sheet comprise a blood modifying agent with an IOB of 0.00-0.60, a melting point of no higher than 45° C., and a water solubility of 0.00-0.05 g in 100 g of water at 25° C. 1. An absorbent article comprising a liquid-permeable top sheet , an absorbent body , a liquid-impermeable back sheet , and a second sheet between the liquid-permeable top sheet and the absorbent body ,wherein the top sheet and the second sheet comprise a blood modifying agent with an IOB of 0.00-0.60, a melting point of no higher than 45° C., and a water solubility of 0.00-0.05 g in 100 g of water at 25° C.2. The absorbent article according to claim 1 , wherein the top sheet has a first region and a second region with lower liquid permeability than the first region claim 1 ,the second sheet has a third region and a fourth region respectively adjacent to the first region and second region of the top sheet in the thickness direction of the absorbent article, andthe top sheet and the third region of the second sheet contain the blood modifying agent.3. The absorbent article according to claim 2 , wherein the first region is a low-basis-weight region having a smaller basis weight than the average basis weight of the top sheet claim 2 , and the second region is a high-basis-weight region having a larger basis weight than the average basis weight of the top sheet.4. The absorbent article according to claim 2 , wherein the first region has a lower fiber density than the second region.5. The absorbent article according to claim 2 , wherein the thickness of the first region is smaller ...

Surface coatings and implantable devices comprising dimeric steroid prodrugs, and uses thereof

The disclosure features surface coatings formed from dimeric steroid prodrugs for the extended delivery of a drug from a surface, and for the treatment of a disease or condition. Also provided herein are drug depots formed from dimeric steroid prodrugs for the extended delivery of a drug for use in combination with implantable medical devices. Said dimeric steroid prodrugs are represented by the formula D1-L-D2, wherein D1 and D2 are independently a steroid radical and L is a linker covalently linking D1 to D2.

MULTI-LAYER BIOMATERIAL FOR TISSUE REGENERATION AND WOUND HEALING

The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects. 1. A composition comprising a first and second layer;the first layer comprising a porous biomaterial matrix; andthe second layer comprising a impermeable biomaterial.2. The composition of claim 1 , wherein the matrix is a structure selected from the group consisting of:foams; hydrogels; electro spun fibers; gels; fiber mats; sponges; 3-dimensional scaffolds; non-woven mats; woven materials; knit materials; fiber bundles;and fibers.3. The composition of any of - claim 1 , wherein the biomaterial is selected from the group consisting of:silk fibroin; PGA; collagen; polyethylene oxide, collagen, fibronectin, keratin, polyaspartic acid, polylysin, alginate, chitosan, chitin, and hyaluronic acid.4Bombyx mori. The composition of any of - claim 1 , wherein the silk fibroin comprises silk fibroin.5. The composition of any of - claim 1 , wherein the first and second layers comprise the same biomaterial.6. The composition of any of - claim 1 , wherein the first and second layers comprise different biomaterials.7. A composition comprising a first and second layer;the first layer comprising a porous silk fibroin matrix; andthe second layer comprising a impermeable silk fibroin film.8. The composition of any of - claim 1 , further comprising an agent.9. The composition of claim 8 , wherein the agent is selected from the group consisting of:an antibiotic; an agent to attract cells; a cell; a stem cell; a ligand; a growth factor; a platelet; and a component of extracellular matrix.10. The composition of any of - claim 8 , wherein the average pore size of the biomaterial matrix is at least 200 μm.11. The composition of any of - claim 8 , wherein the average pore ...

Antimicrobial coatings for medical devices

Antimicrobial formulations and coatings for medical devices and processes therefor are disclosed. The formulations include at least one water permeable polymer with at least one antimicrobial agent in a liquid medium and are prepared by wet milling the components and can form antimicrobial coatings having uniformly dispersed particles having an average size of no greater than 50 microns.

Methods, systems, and compositions for promoting bone growth

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

COATINGS FORMED FROM STIMULUS-SENSITIVE MATERIAL

A coating comprising a stimulus-responsive material and a bioactive agent for controlled release of the bioactive agent and methods of making and using the same are disclosed. 1. An implantable medical device comprising a coating that comprises a stimulus-responsive material and at least one bioactive agent;wherein the bioactive agent comprises a layer of endothelial cells.2. The implantable medical device of wherein the stimulus-responsive material is a material that upon exposure to a stimulus undergoes a change of at least one physical or chemical property such that the release rate of the bioactive agent changes.3. The implantable medical device of wherein the coating comprises at least one other bioactive agent claim 1 , the other bioactive agent being an antiproliferative claim 1 , antiinflammatory claim 1 , immune-modulating claim 1 , antimigratory claim 1 , antineoplastic claim 1 , antimitotic claim 1 , antiplatelet claim 1 , anticoagulant claim 1 , antifibrin claim 1 , antibiotic claim 1 , antioxidant claim 1 , antiallergic claim 1 , or antithrombotic claim 1 , or a pro-healing agent claim 1 , or a combination of these.4. The implantable medical device of wherein the coating comprises at least one other bioactive agent claim 1 , the other bioactive agent being selected from the group consisting of paclitaxel claim 1 , docetaxel claim 1 , estradiol claim 1 , 17-beta-estradiol claim 1 , nitric oxide donors claim 1 , super oxide dismutases claim 1 , super oxide dismutases mimics claim 1 , 4-amino-2 claim 1 ,2 claim 1 ,6 claim 1 ,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO) claim 1 , tacrolimus claim 1 , dexamethasone claim 1 , rapamycin claim 1 , rapamycin derivatives claim 1 , 40-O-(2-hydroxy)ethyl-rapamycin (everolimus) claim 1 , 40-O-(3-hydroxy)propyl-rapamycin claim 1 , 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin claim 1 , 40-O-tetrazole-rapamycin claim 1 , 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578) claim 1 , γ-hiridun claim 1 , clobetasol claim 1 , ...

MALLEABLE IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USE

Provided is a malleable implant configured to fit at or near a bone defect site to promote bone growth, the malleable implant comprising: a biodegradable polymer, mineral particles, and an oxysterol, the implant configured to become moldable upon being wetted with a fluid. Methods of making and use are further provided. 119-. (canceled)20. A method of treating a bone defect site , the method comprising wetting an implant , the implant comprising a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant , mineral particles in an amount of about 0.1 wt % to about 95 wt % of the implant , and an active agent comprising an oxysterol , the implant configured to become moldable upon being wetted with the fluid; molding the implant to a desired shape to fit into the bone defect site; and implanting the implant at the bone defect site.21. A method according to claim 20 , wherein the implant is moldable and comprises autograft claim 20 , allograft and/or xenograft bone particles.22. A method according to claim 20 , wherein the implant is configured to form a coherent mass and be moldable after being wetted with the fluid.23. A method according to claim 20 , further comprising an expandable phase configured to expand upon being wetted with the fluid claim 20 , the expandable phase being in an amount of about 0.1 wt % to about 5.0 wt % of the implant.24. A method according to claim 23 , wherein the expandable phase is in an amount of about 2.0 wt % to about 4.0 wt % of the implant claim 23 , the biodegradable polymer is in an amount of about 8.0 wt % to about 13 wt % of the implant claim 23 , the mineral particles are in an amount of about 50 wt % to about 80 wt % of the implant claim 23 , and the oxysterol is in an amount of about 5.0 wt % to about 45 wt % of the implant.25. A method according to claim 23 , wherein the expandable phase comprises carboxymethyl cellulose claim 23 , hydroxymethyl cellulose claim 23 , hydroxypropyl methylcellulose ...

GEL FOR TREATING PERIOCULAR AND/OR ORBITAL PATHOLOGIES AND CONDITIONS

A method comprising treating a periocular wound in a subject, comprising topically administering to the periocular wound a composition comprising at least one thermoresponsive gel. 1. A method comprising treating a periocular wound in a subject , comprising topically administering to the periocular wound a composition comprising at least one thermoresponsive gel.2. The method of claim 1 , further comprising treating an ocular wound simultaneously with treating the periocular wound.3. The method of claim 1 , wherein the wound is treated prior to surgery.4. The method of claim 1 , wherein the composition is administered to cover an entire wound surface.5. The method of claim 1 , wherein the composition is placed over the wound for a time period of not more than 72 hours.6. A method for treating an ocular condition associated with an orbit in a subject claim 1 , comprising intraorbitally administering to the subject in need thereof a composition comprising at least one non-degradable stimuli-responsive gel.7. The method of claim 6 , wherein the ocular condition is enophthalmia claim 6 ,microphthalmia, anophthalmia, inflammation, infection or wound healing.8. The method of claim 6 , wherein the ocular condition is enophthalmia.9. The method of claim 7 , wherein the inflammation is due to trauma or surgery.10. A method comprising providing orbital volume filling or mechanical support for an eye or a combination of both wherein the method comprises intraorbitally administering to a subject in need thereof a composition comprising at least one thermoresponsive gel.11. The method of claim 10 , wherein the composition is administered prior to orbital floor construction.12. The method of claim 10 , wherein the method comprises injecting the composition into the orbit.13. The method of claim 6 , further comprising maintaining the gel within the subject for a period of at least 12 months.14. The method of claim 13 , wherein the gel is stable for at least 12 months.15. The ...

Materials reducing formation of hypochlorite

The invention relates to electrochemical wound dressings wherein potential damage to healthy cells and granulating tissue induced by hypochlorite and/or hypochlorous acid is reduced by enabling effective removal or build-up of substantial concentrations thereof through use of catalysts and/or scavenging/sacrificing agents. In another aspect, the present invention relates to the use of the latter materials in medical devices and articles.

HALOGENATED COMPOUNDS, PROCESS AND USES THEREOF

The present disclosure relates to halogenated fatty acid lactylates, in particular to chlorinated fatty acid lactylates. 2. The compound of claim 1 , wherein R is a C-Calkyl chain comprising at least one halogen selected from the group consisting of Cl claim 1 , Br and I claim 1 , wherein the at least one halogen is located at any position of said chain.3. The compound of claim 1 , wherein R is a C-Calkyl chain comprising at least one Cl located at any position of said chain.4. The compound of claim 1 , wherein R is a C-Calkyl chain comprising at least one halogen selected from the group consisting of Cl claim 1 , Br and I claim 1 , located at any position of said chain.6. The compound of claim 5 , wherein R claim 5 , R claim 5 , Rare each independently H claim 5 , CH claim 5 , or Cl.7. The compound of claim 5 , wherein at least one of R claim 5 , Ror Ris Cl.8. The compound of claim 1 , wherein Ris H.9. The compound of claim 1 , wherein Ris CH.10. The compound of claim 5 , wherein Ris H or Cl claim 5 , Ris H or Cl claim 5 , and Ris Cl or CH.12. (canceled)13. A method for treating or preventing a microbial infection in a subject claim 1 , the method comprising administering the compound of to the subject.14. The method of claim 19 , wherein the bacterial infection is a coagulase-negative staphylococci infection.15Staphylococcus aureus. The method of claim 14 , wherein the coagulase-negative staphylococci infection is a infection.16. A pharmaceutical composition comprising a therapeutically effective amount of the compound of and a pharmaceutically acceptable excipient.17. A medical device comprising the compound of as a biofilm inhibitor.18. A cyanobacterium strain with a deposit under the number 1471/1 of Aug. 8 claim 1 , 2019 at CCAP.19. The method of claim 13 , wherein the microbial infection is a bacterial infection.20. The method of claim 19 , wherein the bacterial infection is selected from the group consisting of endocarditis claim 19 , osteomyelitis claim 19 ...

Antimicrobial coatings for medical devices and processes for preparing such coatings

Antimicrobial formulations and coatings for medical devices and processes therefor are disclosed. The formulations include at least one water permeable polymer with at least one antimicrobial agent in a liquid medium and are prepared by wet milling the components and can form antimicrobial coatings having uniformly dispersed particles having an average size of no greater than 50 microns.

COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USE

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth, the compression resistant implant comprising porous ceramic particles in a biodegradable polymer, and an oxysterol disposed in or on the compression resistant implant. Methods of making and use are further provided. 112-. (canceled)13. A method of treating a bone defect , the method comprising implanting a compression resistant implant at or near the bone defect to promote bone growth , the compression resistant implant comprising porous ceramic particles in an amount of about 30 wt % to about 99.5 wt % in a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % based on a total weight of the implant , and an oxysterol disposed in or on the compression resistant implant so as to treat the bone defect.14. A method according to claim 13 , wherein the implant is not compressed any more than about 20% in any one direction for a period of at least about 30 days in vivo.15. A method according to claim 13 , wherein (i) the porous ceramic particles are uniformly distributed throughout the implant; (ii) the oxysterol is uniformly distributed throughout the biodegradable polymer; and/or (iii) the oxysterol is uniformly distributed throughout the porous ceramic particles.16. A method according to claim 13 , wherein the porous ceramic particles form a ceramic skeleton claim 13 , the skeleton having pores in the range of 1-10 mm in diameter claim 13 , and a total porosity of 50-98%.17. A method according to claim 13 , wherein the porous ceramic particles form a ceramic skeleton disposed continuously throughout the implant claim 13 , and the implant has a compression strength of about 2 MPa to about 40 MPa18. A method for making a compression resistant implant claim 13 , the method comprising adding porous ceramic particles in an amount of about 30 wt % to about 99.5 wt % to a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % based on a ...

ABSORBENT ARTICLES COMPRISING GLYCERIDE COPOLYMERS

The present invention relates to absorbent articles comprising species of glyceride copolymers that provide unexpectedly improved softening performance and formulability. 1A) a glyceride copolymer having formula (I):. An absorbent article comprising a composition, said composition comprising [ [{'sup': 1', '2', '3', '4', '5, 'sub': 1-24', '1-24', '2-24', '2-24, 'claim-text': [{'sup': 1', '3, 'Rand R,'}, {'sup': 2', '5, 'Rand R,'}, {'sup': 1', '4, 'Rand an adjacent R,'}, {'sup': 2', '4, 'Rand an adjacent R,'}, {'sup': 3', '4, 'Rand an adjacent R,'}, {'sup': 5', '4, 'Rand an adjacent R, or'}, {'sup': '4', 'any two adjacent R'}], 'each R, R, R, R, and Rin the glyceride copolymer is independently selected from the group consisting of an oligomeric glyceride moiety, a Calkyl, a substituted Calkyl wherein the substituent is one or more —OH moieties, a Calkenyl, or a substituted Calkenyl wherein the substituent is one or more —OH moieties; and/or wherein each of the following combinations of moieties may each independently be covalently linked, 'such that the covalently linked moieties form an alkenylene moiety;', {'sup': 1', '2, 'sub': 1-32', '1-32', '2-32', '2-32, 'each Xand Xin said glyceride copolymer is independently selected from the group consisting of a Calkylene, a substituted Calkylene wherein the substituent is one or more —OH moieties, a Calkenylene or a substituted Calkenylene wherein the substituent is one or more —OH moieties;'}, {'sup': 1', '2', '3', '2', '3, 'sub': '2', 'two of G, G, and Gare —CH—, and one of G, and Gis a direct bond;'}, {'sup': 4', '5', '6', '4', '5', '6', '4', '5', '6', '4', '5', '6, 'sub': '2', 'for each individual repeat unit in the repeat unit having index n, two of G, G, and Gare —CH—, and one of G, G, and Gis a direct bond, and the values G, G, and Gfor each individual repeat unit are independently selected from the values of G, G, and Gin other repeating units;'}, {'sup': 7', '8', '9', '7', '8', '9, 'sub': '2', 'two of G, G, and ...

WOUND MANAGEMENT SYSTEM AND METHODS OF USING

A wound management system can comprise a surgically acceptable adhesive disposed over a wound and a surgically acceptable film repositionably disposed over the surgically acceptable adhesive, and methods of managing a wound involving the same.

Degradable hemostatic sponge and preparation method and use thereof, and degradable drug-loaded hemostatic sponge

The present disclosure belongs to the technical field of hemostatic materials, and specifically relates to a degradable hemostatic sponge and a preparation method and use thereof, and a degradable drug-loaded hemostatic sponge. The degradable hemostatic sponge provided by the present disclosure is prepared from raw materials including a crosslinking-modified starch and a cellulose through freeze-drying, where a mass ratio of the crosslinking-modified starch to the cellulose is (0.2-5):1. The degradable hemostatic sponge provided by the present disclosure has a high water-absorbing rate and a large water-absorbing capacity, shows a high support strength and a long support time after water absorption, and is made from plant-derived raw materials and thus may be completely biodegraded. The degradable drug-loaded starch hemostatic sponge provided by the present disclosure has a drug-loaded coating attached to a surface of the sponge, where the drug is slowly released while a support is maintained.

SUSTAINED-RELEASE DRUG CARRIER COMPOSITION

The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block-co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof. 145-. (canceled)46. A non-liposomal matrix composition comprising:(a) a biocompatible non-biodegradable polymer non-covalently associated with a first lipid comprising at least one sterol having a polar group;(b) a second lipid comprising at least one phospholipid having fatty acid moieties having at least 14 carbons, wherein the biocompatible non-biodegradable polymer is not bonded to the second lipid; and(c) at least one pharmaceutically active agent;wherein the matrix composition is lipid saturated and when maintained in an aqueous environment provides sustained release of the pharmaceutically active agent.47. The matrix composition of claim 46 , wherein said phospholipid is a phosphatidylcholine having fatty acid moieties having at least 14 carbons.48. The matrix composition of claim 47 , wherein the phosphatidylcholine is selected from the group consisting of: 1 claim 47 ,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) claim 47 , 1 claim 47 ,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1 claim 47 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).49. The matrix composition of claim 46 , wherein the matrix composition further comprises a biodegradable polymer.50. The matrix composition of claim 49 , wherein the non-biodegradable polymer and the biodegradable polymer form a block co-polymer.51. The matrix composition of claim 46 , wherein the non-biodegradable polymer is selected from the group consisting of polyethylene glycol (PEG) claim 46 , PEG acrylate claim 46 , PEG ...

METHODS FOR COATING IMPLANT SURFACES TO TREAT SURGICAL INFECTIONS

Methods for treating infection at the site of implantation of an orthopedic device in a human or animal subject. The methods include removing the orthopedic device, and implanting a replacement device. A surface of the replacement device is coated with an infection-inhibiting composition having a waxy matrix. The waxy matrix includes an infection-inhibiting material, such as a lipid, an antimicrobial agent, or a combination of a lipid and an antimicrobial agent. 1. A method for treating infection at a site of implantation of an orthopedic device in a human or animal subject , comprising(a) removing the orthopedic device; and(b) implanting a replacement device, a surface of which is coated with an infection-inhibiting composition having a waxy matrix, the waxy matrix comprising an infection-inhibiting material selected from the group consisting of a lipid, an antimicrobial agent, and mixtures thereof.2. The method for treating infection according to claim 1 , wherein the waxy matrix comprises a lipid selected from the group consisting of fatty acids claim 1 , triacylglycerols claim 1 , diacylglycerols claim 1 , glycerophospholipids claim 1 , and mixtures thereof.3. The method for treating infection according to claim 2 , wherein the waxy matrix comprises about 90% or more claim 2 , by weight of the waxy matrix claim 2 , of phosphatidylcholine.4. The method for treating infection according to claim 1 , wherein the infection-inhibiting composition comprises an antimicrobial agent selected from the group consisting of antibiotics claim 1 , antimicrobial peptides claim 1 , synthetic mimics of antimicrobial peptides claim 1 , disinfectants claim 1 , antimicrobial metal ions claim 1 , epsilon polylysine claim 1 , sugar alcohols claim 1 , essential oils claim 1 , and mixtures thereof.5. The method for treating infection according to claim 4 , wherein the antimicrobial agent is selected from the group consisting of fosfomycin claim 4 , rifampin claim 4 , tetracyclines claim ...

IMPLANT FOR SUBCUTANEOUS IMPLANTATION

The invention relates to an implant for subcutaneous implantation having a substantially cylindrical, conical or spiral-shaped base body which has a lateral surface. The base body consists of a completely resorbable biodegradable polymer. The implant is further configured for blunt implantation. In addition, the biodegradable polymer is enriched with a medicinally relevant active ingredient. 112.-. (canceled)13. An implant for subcutaneous implantation ,having a substantially cylindrical, conical or spiral-shaped base body which has a lateral surface,wherein the base body consists of a completely resorbable biodegradable polymer,wherein the implant is configured for blunt implantation,wherein there are provided on the lateral surface of the base body, in the case of a cylindrical or conical base body, protruding wings which are integrally formed with the base body,wherein the biodegradable polymer is enriched with a medicinally relevant active ingredient.141. The implant according to claim ,characterized in thatthe wings are arranged circumferentially at the entire periphery of the lateral surface, in that the wings, in a radial cross-section of the implant, have a surface substantially similar to a triangle.151. The implant according to claim ,characterized in thatthe wings are configured in the manner of a spiral, whereby they form at least one screw thread.161. The implant according to claim ,characterized in thatthe implant is configured to be self-inserting and/or self-tapping on rotation about the longitudinal axis of the base body.171. The implant according to claim ,characterized in thatit has a resorption rate of at least three months.181. The implant according to claim ,characterized in thatit has a blunt or rounded tip.191. The implant according to claims ,characterized in thatthe medicinally relevant active ingredient is a competitive inhibitor of type 1 and/or type 2 5-α-reductase, in particular dutasteride, finasteride and/or minoxidil.201. The implant ...

HIGHLY ABSORBENT RESISTANT WASHABLE AND REUSABLE UNDERGARMENTS, METHODS OF USE, KITS AND USES THERETO

An undergarment article has a fabric a fabric layer for wearing about a pelvic region of a person, a water-repellent layer coupled to a crotch portion of the fabric layer to form an inner chamber, and an inner pad disposed within the inner chamber between the water-repellent layer and the fabric layer. The inner pad is resistant to heat and includes a liquid-absorbent layer and a waterproof layer. The liquid-absorbent layer contacts the water-repellent layer and is effective for absorbing a volume of liquid greater than 2 fluid ounces. The waterproof layer is effective for restricting liquid from reaching the fabric layer. The crotch portion of the fabric layer and the water-repellent layer can be substantially elastic in at least one of a lateral direction and a longitudinal direction of the crotch portion. Methods for using the undergarment, kits and uses of the undergarment are also disclosed. 113-. (canceled)14. A method for reducing discomfort and/or embarrassment caused by incontinency , the method comprises contacting an undergarment with a C8-C16 unsaturated fatty acid and/or an essential oil and wearing the undergarment , wherein the undergarment comprises:a fabric layer for wearing about a pelvic region of a person;a water-repellent layer coupled to the fabric layer, the water-repellent layer and a crotch portion of the fabric layer defining an inner chamber, the water-repellent layer being disposed for contacting a genital area of a person wearing the undergarment; andan inner pad disposed within the inner chamber between the water-repellent layer and the fabric layer, the inner pad being resistant to heat and comprising an liquid-absorbent layer and a waterproof layer, the liquid-absorbent layer contacting the water-repellent layer and being effective for absorbing a volume of liquid greater than 2 fluid ounces, the waterproof layer being effective for restricting liquid from reaching the fabric layer and the water-repellent layer being effective for ...

Implants having a drug load of an oxysterol and methods of use

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.

METHODS FOR REDUCING OR PREVENTING TRANSPLANT REJECTION IN THE EYE AND INTRAOCULAR IMPLANTS FOR USE THEREFOR

Methods for reducing or preventing transplant rejection in the eye of an individual are described; comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer. 1. A solid bioerodible implant for reducing or preventing transplant rejection in an eye of an individual , the implant comprising about 50% by weight of dexamethasone , about 15% by weight of hydroxypropyl methylcellulose (HPMC) , and about 35% by weight of Resomer RG 502H PLGA.2. A solid bioerodible implant for reducing or preventing transplant rejection in an eye of an individual , the implant comprising about 60% by weight of dexamethasone , about 30% by weight of Resomer RG 502H PLGA , and about 10% by weight of Resomer RG 502 PLGA.3. A method for reducing or preventing transplant rejection in an eye of an individual , the method comprising:a) performing an ocular transplant procedure on an eye of an individual; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'b) implanting in the eye a solid bioerodible implant according to , thereby reducing or preventing transplant rejection.'}4. A method for reducing or preventing transplant rejection in an eye of an individual , the method comprising:a) performing an ocular transplant procedure on an eye of an individual; and{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'b) implanting in the eye a solid bioerodible implant according to , thereby reducing or preventing transplant rejection.'} This application is a continuation of U.S. application Ser. No. 11/852,223, filed Sep. 7, 2007, and hereby incorporated by reference, which is a divisional of U.S. application Ser. No. 11/738,409, filed Apr. 20, 2007, now U.S. Pat. No. 7,625,582, which is a divisional of U.S. application Ser. No. 11/180,079, filed Jul. 11, 2005, now U.S. Pat. No. 7,767,223, which is a continuation of U.S. application Ser. No. 10/744,560, filed Dec. 22, 2003, now ...

DENDRIMER-BIOADHESIVE POLYMER HYDROGEL NANOGLUE AND USE THEREOF

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided. 1. A nanoglue comprisingdendrimer, andbioadhesive polymers,wherein the dendrimer molecules and the bioadhesive polymers are crosslinkable to each other upon exposure to one or more external stimuli or one or more physiological conditions within tissue.2. The nanoglue of claim 1 , wherein the composition further comprises therapeutic claim 1 , prophylactic claim 1 , or diagnostic agent and optionally claim 1 , wherein the therapeutic claim 1 , prophylactic claim 1 , or diagnostic agent is conjugated to or complexed with dendrimer.3. (canceled)4. The nanoglue of comprising agent selected from the group consisting of anti-inflammatory drugs claim 2 , anti-infective agents claim 2 , anti-glaucoma agents claim 2 , agents that lower intraocular pressure (TOP) claim 2 , anti-angiogenesis agents claim 2 , growth factors claim 2 , and growth factors.5. The nanoglue of comprising a diagnostic agent selected from the group consisting of paramagnetic molecules claim 2 , fluorescent compounds claim 2 , magnetic molecules claim 2 , radionuclides claim 2 , x-ray imaging agents claim 2 , and contrast media.6. The nanoglue ...

CROSS-LINKED FATTY ACID-BASED BIOMATERIALS

Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided. 120-. (canceled)21. A cured biomaterial comprising:fatty acids cross-linked to each other via cross-linking bridges, wherein the fatty acids are derived from fish oil;wherein the cured biomaterial is hydrolysable in vivo and a composition of the fatty acids before curing comprises at least about twenty-five percent saturated fatty acids and at least about thirty percent polyunsaturated fatty acids in terms of area % by gas chromatography fatty acid profile.22. The cured biomaterial of claim 21 , wherein the fatty acids comprise approximately 5-50% Cfatty acids in terms of area % by gas chromatography fatty acid profile.23. A medical device having a coating formed by the cured biomaterial of .24. The cured biomaterial of claim 21 , wherein the fatty acids are cross-linked to each other by ester and lactone bonds.25. The cured biomaterial of claim 21 , wherein the polyunsaturated fatty acids are primarily Cfatty acids or longer.26. The cured biomaterial of claim 21 , wherein the polyunsaturated fatty acids are primarily Cand Cfatty acids.27. The cured biomaterial of claim 21 , wherein the cross-linking bridges include a combination of peroxide bridges claim 21 , ether bridges claim 21 , and hydrocarbon bridges.28. A cured biomaterial comprising:fatty acids cross-linked to each other via cross-linking bridges, wherein the fatty acids are derived from fish oil;wherein the cured biomaterial is hydrolysable in vivo and a composition of the fatty acids before curing comprises at least five different fatty acid species ...

Urine measurement device and method

A urine handling system capsule for releasing an oil mixture in the lumen of a urine handling system, the capsule comprising a capsule wall defining a space filled with an oil mixture, wherein the oil mixture comprises 90-100% of an oil selected from the group consisting of silicone fluids and mineral oils or a mixture thereof, and having a viscosity of at most 600 cSt, and wherein the capsule wall is made of a water-soluble material. A urine measurement system comprising an oil mixture arranged in the luminal space of the measurement system. A method for inhibiting impairment of functionality and measurement accuracy in a urine measurement system comprising applying an oil mixture to the inner surfaces of the urine measurement system. Use of an oil mixture in treatment of luminal surfaces of a urine handling system.

Nanostructure Surface Coated Medical Implants and Methods of Using the Same

Compositions including a surface or film comprising nanofibers, nanotubes or microwells comprising a bioactive agent for elution to the surrounding tissue upon placement of the composition in a subject are disclosed. The compositions are useful in medical implants and methods of treating a patient in need of an implant, including orthopedic implants, dental implants, cardiovascular implants, neurological implants, neurovascular implants, gastrointestinal implants, muscular implants, and ocular implants. 1106-. (canceled)107. A method comprising administering to a subject a composition that comprises a surface or film comprising a vertically oriented array of a plurality of nanotubes or microwells ,wherein a bioactive agent is filled into the nanotubes or microwells themselves,wherein a first end of the array of the plurality of filled nanotubes or microwells is in contact with the surface or film, andwherein the plurality of nanotubes or microwells is capped with a polymeric erodible capping film to provide for delayed elution of the bioactive agent from within the nanotubes or microwells to the surrounding tissue upon placement in a subject and erosion of the capping film.108. The method of claim 107 , wherein the subject is a human.109. The method of claim 107 , wherein the subject is a laboratory claim 107 , agricultural claim 107 , domestic or wild animal.110. The method of claim 107 , wherein the composition is an orthopedic implant claim 107 , a dental implant claim 107 , a cardiovascular implant claim 107 , a neurological implant claim 107 , a neurovascular implant claim 107 , a gastrointestinal implant claim 107 , a muscular implant claim 107 , or an ocular implant.111. The method of claim 110 , wherein the composition is configured for enhancing osseointegration of the orthopedic implant.112. The method of claim 107 , wherein the composition is a patch for localized delivery of said bioactive agent to a soft tissue.113. The method of claim 107 , wherein ...

CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE

The present disclosure provides click-crosslinked hydrogels and methods of use. 2. The hydrogel according to claim 1 , wherein:{'img': {'@id': 'CUSTOM-CHARACTER-00005', '@he': '3.22mm', '@wi': '6.01mm', '@file': 'US20170189581A1-20170706-P00001.TIF', '@alt': 'custom-character', '@img-content': 'character', '@img-format': 'tif'}, 'bond is a single bond;'}{'sup': 1', '2N, 'sub': 1', '6', '0', '3, 'Ris —C-Calkyl-NR—, or —C-Calkyl-C(O)—;'}{'sup': '2', 'sub': 1', '6', '1', '6', '1', '6', '1', '6, 'Ris a bond or aryl optionally substituted with halogen, hydroxy, C-Calkyl, C-Calkoxy, (C-Calkyl)amino, or di(C-Calkyl)amino;'}{'sup': 3', '2N, 'sub': 1', '6', '0', '3, 'Ris —C-Calkyl-NR—, or —C-Calkyl-C(O)—; and'}{'sup': '4', 'sub': 1', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'Ris hydrogen, C-Calkyl, or heteroaryl, wherein heteroaryl is optionally substituted with halogen, hydroxy, C-Calkyl, C-Calkoxy, (C-Calkyl)amino, or di(C-Calkyl)amino.'}3. The hydrogel according to claim 2 , wherein Rand Rare both -methyl-NR—; or Rand Rare both —C(O)—.5. The hydrogel of claim 1 , wherein the first polymer and the second polymer are independently water-soluble polymers.6. The hydrogel of claim 1 , wherein the first polymer and the second polymer are the same polymer.7. The hydrogel of claim 1 , wherein the first polymer and the second polymer are independently selected from the group consisting of alginate claim 1 , chitosan claim 1 , polyethylene glycol (PEG) claim 1 , gelatin claim 1 , hyaluronic acid claim 1 , collagen claim 1 , chondroitin claim 1 , agarose claim 1 , polyacrylamide claim 1 , and heparin.8. The hydrogel of claim 1 , wherein the first polymer and the second polymer comprise a polysaccharide9. The hydrogel of claim 1 , wherein the first polymer and the second polymer are independently selected from group consisting of alginate claim 1 , chitosan claim 1 , and gelatin.10. The hydrogel of claim 9 , wherein the first polymer and the second polymer are independently ...

DRUG-COATED BALLOON

Described here are devices, systems, and methods for treating conditions or diseases of the nose, ear, or throat with an expandable device having a drug coating. The expandable devices may be delivered to a body cavity in a low-profile configuration and expanded to contact surrounding tissue. The expandable devices may deliver or release the drug coating to the tissue. Multiple expansions of a single device may be employed during treatment. Various coating excipients and manufacturing parameters for the expandable devices may also be adjusted to enhance or slow transfer of the drug coating and/or release of the drug to the target tissue site. The drug transferred to the tissue may act as an in situ depot that enables maintenance of a therapeutic level of locally delivered drug for a desired time period after removal of the expandable devices. 1. An expandable device configured for delivering a therapeutic agent to a nasal , otic , or throat tissue site , comprising:the expandable device having a low-profile configuration and an expanded configuration;an external surface of the expandable device;a drug coating on the external surface where the drug coating comprises a mixture of crystalline and amorphous forms of a drug; andan internal volume of the expandable device configured to receive fluid.2. The device of claim 1 , wherein the drug coating is applied to the external surface of the expandable device by a process claim 1 , comprising:providing the expandable device having a low-profile configuration and an expanded configuration;treating the expandable device by a plasma process;spray coating the expandable device in the expanded configuration with a drug;exposing the expandable device to a solvent vapor; andfolding the expandable device into the low-profile configuration.3. The device of claim 2 , wherein the drug coating is applied to the external surface of the expandable device by a process further comprising priming the expandable device with a hydrophilic ...

Oxygenated Oil Ointment

An oxygenated oil ointment is made, for example, by stirring or agitating plant-based oil while injecting a gas into the plant-based oil, resulting in a coagulated ointment that is beneficial for topical application. In one example, the plant-based oil is olive oil and the gas includes ozone, which is known to kill pathogens. For some plant-based oils, the ozone increases amounts of peroxide in the plant-based oils. Once the olive oil coagulates with the ozone, the resulting ointment retains some of the ozone gas until the ointment is applied on the skin for treatment of, for example, cuts and sores. In some ointments, the pH of the plant-based oil is increased by adding one or more alkaline materials to the plant-based oil before coagulation occurs. This increase in alkalinity improves the ointment's ability to give off ozone and oxygen. 1. A coagulated composition for topical application , the composition comprising:a plant-based oil mixed with at least 0.01% by weight of an alkaline material; anda gas, the gas infused into the plant-based oil and the alkaline material.2. The coagulated composition of claim 1 , wherein the alkaline material is one or more materials selected from the group consisting of calcium chloride claim 1 , magnesium sulfide claim 1 , sodium meta-silicate claim 1 , and sulfated castor oil.3. The coagulated composition of claim 1 , wherein the alkaline material has a pH of approximately 13 and comprises a mixture made by mixing 750 milliliters of ion-depleted HO having approximately 17 megohms-cm of resistance (e.g. ultra-pure water having an electrical resistance of 16-26 megohms) with 330 milliliters of calcium chloride claim 1 , 660 milligrams of magnesium sulfate claim 1 , 47 claim 1 ,500 milligrams of Sodium silicate pentahydrate claim 1 , and 1000 milligrams sodium benzoate which is heated to 80 degrees Celsius for ten minutes claim 1 , then cooled to room temperature for ten minutes claim 1 , at which time 100 milliliters of sulfated ...

Water Soluble Farnesol Analogs and Their Use

Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group). 1. A farnesol analog comprising a hydrophilic end group attached to farnesol via a covalent linkage , wherein the hydrophilic end group defines a hydroxyl end group or a carboxylic acid end group , and wherein the covalent linkage comprises an ester group or an ether group.2. The farnesol analog as in claim 1 , wherein the covalent linkage comprises a first ester group.4. The farnesol analog as in claim 3 , wherein n is 2 claim 3 , 3 claim 3 , or 4.5. The farnesol analog as in claim 4 , wherein the hydrophilic end group comprises a second ester group.7. The farnesol analog as in claim 6 , wherein n is 2 claim 6 , 3 claim 6 , or 4; andwherein m is 2, 3, or 4.8. The farnesol analog as in claim 1 , wherein the covalent linkage comprises an ether group claim 1 , and wherein the hydrophilic end group defines a hydroxyl end group.10. The farnesol analog as in claim 9 , wherein n is 2 claim 9 , 3 claim 9 , or 4.12. The farnesol analog as in claim 8 , wherein the farnesol analog comprises a monosaccharide covalently attached to the farnesol via an ether linkage.14. The farnesol analog as in claim 1 , wherein the farnesol analog has a solubility in water that is 10 grams per 100 grams of water or greater.15. A wipe comprising a web that includes a plurality of fibers claim 1 , wherein the web is coated with a treatment composition claim 1 , the treatment composition comprising the farnesol analog according to .16. An absorbent article comprising:a liquid impermeable outer cover;a liquid permeable bodyside liner;an absorbent body disposed between the outer cover and bodyside liner; and{'claim-ref': {'@idref': 'CLM-00001', ...

CURED GEL AND METHOD OF MAKING

A cured non-polymeric gel including a plurality of non-polymeric cross-links. The non-polymeric cross-links result from curing an oil or oil composition at selected curing conditions to achieve a desired amount of cross-linking to form the non-polymeric gel. The desired amount of cross-linking is selected based on a desired rate of degradation of the gel after the gel is implanted. The oil or oil composition comprises one or more of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or alpha-linolenic acid (ALA). 110-. (canceled)11. A method of forming a cured non-polymeric gel , comprising:determining a desired amount of non-polymeric cross-linking desired within an oil or oil composition, the oil or oil composition comprising one or more of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or alpha-linolenic acid (ALA); andcuring the oil or oil composition with selected curing conditions to achieve a sufficient amount of non-polymeric cross-linking within the oil or oil composition, so as to form the non-polymeric gel, wherein the cured non-polymeric gel comprises a plurality of non-polymeric cross-links resulting from curing the oil or oil composition at the selected curing conditions to achieve the sufficient amount of cross-linking to form the cured non-polymeric gel, wherein the amount of cross-linking is selected based on a desired rate of degradation of the gel after the gel is implanted within a patient, and wherein the oil or oil composition comprises one or more of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or alpha-linolenic acid (ALA).12. The method of claim 11 , wherein the gel further comprises at least one therapeutic agent and the method further comprises releasing the therapeutic agent from the gel at a predetermined rate determined by the curing at the selected curing conditions.13. The method of claim 11 , wherein the oil or oil composition comprises at least one component selected from a group of components consisting ...

Drug-coated balloon

Described here are devices, systems, and methods for treating conditions or diseases of the nose, ear, or throat with an expandable device having a drug coating. The expandable devices may be delivered to a body cavity in a low-profile configuration and expanded to contact surrounding tissue. The expandable devices may deliver or release the drug coating to the tissue. Multiple expansions of a single device may be employed during treatment. Various coating excipients and manufacturing parameters for the expandable devices may also be adjusted to enhance or slow transfer of the drug coating and/or release of the drug to the target tissue site. The drug transferred to the tissue may act as an in situ depot that enables maintenance of a therapeutic level of locally delivered drug for a desired time period after removal of the expandable devices.

Prosthetic Heart Valves

Prosthetic heart valves having a conical shaped base valve structure formed from collagenous mammalian tissue and an expandable stent structure. The base valve structure includes a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, wherein the elongated ribbon members are positioned adjacent each other and form a plurality of fluid flow modulating regions that open when fluid into and through the base valve structure exhibits a positive pressure relative to the exterior pressure, i.e., a positive pressure differential, wherein the fluid is allowed to be transmitted out of the base valve structure, and transition to a closed configuration when the pressure differential between the interior valve pressure and exterior pressure reduces, wherein the fluid is restricted from flowing out of the base valve structure. The expandable stent structure includes a plurality of tethers adapted to pierce cardiovascular tissue and, thereby, position the base valve structure and, thereby, prosthetic valves formed therewith on said heart valve annulus. 1. A prosthetic valve for modulating fluid flow through a cardiovascular structure during cardiac cycles of a heart , comprising:a base valve structure and an expandable stent structure,said base valve structure comprising collagenous tissue derived from a first mammalian tissue source,said base valve structure further comprising an internal region, an open proximal valve annulus engagement end and a distal valve structure end, said open proximal valve annulus engagement end being configured and adapted to engage a heart valve annulus, receive said fluid flow therein and direct said fluid flow into said internal region of said base valve structure,said base valve structure further comprising a plurality of elongated ribbon members that extend from said open proximal valve annulus engagement end to said distal valve structure end, each of said plurality of elongated ribbon members ...

PROGESTERONE-CONTAINING COMPOSITIONS AND DEVICES

Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the invention provides a drug eluting device, such as a drug eluting stent, with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices. 1. A drug eluting medical device comprising:a medical device;an eluting mechanism selected from the group consisting of a coating, reservoir, pore, duct, channel, chamber, side-port, and lumen; anda composition consisting essentially of (i) progesterone or a progesterone analog or (ii) progesterone or a progesterone analog and one or more of vitamin E and conjugated linoleic acid; the medical device comprises the eluting mechanism;', 'the eluting mechanism elutes the composition;', 'the progesterone is present in a therapeutically effective amount; and', 'the progesterone is eluted in vivo., 'wherein'}2. The device of claim 1 , wherein:the eluting mechanism is proximal to, distal to, lateral to, underneath, embedded within or on the device; andthe eluting mechanism elutes progesterone in vivo.3. The device of claim 1 , comprising at least one coating layer; wherein:the at least one coating layer comprises the composition; andthe at least one coating layer is formed on at least a portion of a surface of the medical device.4. The device of claim 1 , wherein the composition ...

Modular bioresorbable or biomedical, biologically active supramolecular materials

The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or biomedical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and bioresorption properties). The supramolecular bioresorbable or biomedical material is especially suitable for biomedical applications such as controlled release of drugs, materials for tissue-engineering, materials for the manufacture of a prosthesis or an implant, medical imaging technologies.

Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal

Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue. 1a lattice having a matrix of interconnected pores which form surfaces in three dimensions;an inert, bio-compatible material covering the surfaces; andat least one of a hyaluronan, dexamethasone, protein, peptide, transcript factor, cytokine, therapeutic agent, chitosan, polymer, osteogenic gene and growth factor, covering the'material.. A three-dimensional tissue scaffold-implant for supporting tissue on-growth, the scaffold-implant comprising: The application claims the benefit of U.S. Provisional Application No. 60/539,661, filed on Jan. 27, 2004, which is incorporated herein in its entirety.The invention relates to tissue generation. More particularly, the invention relates to three-dimensional tissue generation by ex vivo three-dimensional cell culture methods using porous, three-dimensional tissue scaffold-implants.The current trend of tissue engineering technology is toward the development of biomaterials for repairing tissue defects or to enhance fixation of implants to the host tissue. Basic requirements include a scaffold-implant conductive to cell attachment and maintenance of cell function, together with a rich source of progenitor cells. Biomaterials in combination with cells from ex-vivo cultures will not only accelerate the tissue healing, but also increase the ...

LYOPHILIZED MOLDABLE IMPLANTS CONTAINING AN OXYSTEROL

Provided is a lyophilized implant configured to fit at or near a bone defect to promote bone growth, the lyophilized implant containing a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant, mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant, and an oxysterol in an amount of about 5 wt. % to about 90 wt. % of the implant. Methods of making and using the implant are further provided. 118-. (canceled)19. A method of treating a bone defect in a patient in need thereof , the method comprising implanting at or near the bone defect a lyophilized implant hydrated with a fluid , the lyophilized implant comprising a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant , mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant , and an oxysterol in an amount of about 0.01 wt. % to about 90 wt. % of the implant , wherein the oxysterol is in dihydrate form.20. A method of treating a bone defect of claim 19 , wherein the lyophilized implant further comprises an expandable phase material in an amount from about 2 wt. % to about 4 wt. %.21. A method of treating a bone defect of claim 19 , wherein the fluid is water claim 19 , sodium chloride claim 19 , dextrose claim 19 , Lactated Ringer's solution claim 19 , PBS claim 19 , blood claim 19 , bone marrow aspirate claim 19 , bone marrow fractions or a combination thereof in an amount from about 0.25 mL to about 50 mL.22. A method for making a lyophilized implant of claim 20 , wherein the expandable phase material is carboxymethylcellulose claim 20 , pectin or chitosan.23. A method of treating a bone defect of claim 19 , wherein the volume of the lyophilized implant comprises from about ¾ mL to about 10 mL.24. A method of treating a bone defect in a patient in need thereof claim 19 , the method comprising implanting at or near the bone defect a lyophilized implant hydrated with a fluid claim 19 , the ...

SURFACE TREATMENTS

An antimicrobial surface treatment method comprising the step of contacting a stainless-steel surface with an aqueous dispersion of at least one functional-lipid construct where the lipid moiety is a phosphatidylethanolamine and the functional moiety confers the antimicrobial activity. 1. An antimicrobial surface treatment method comprising the step of contacting the surface of an object with an aqueous dispersion of at least one functional-lipid construct where the lipid is a di-acyl , di-alkenyl or di-alkyl glycerophospholipid and the functional moiety of the construct is selenide.2. The method of where the object is a surgical dressing or implant.3. The method of where the object is a surgical implant.4. The method of where the surface is stainless steel.5. The method of where the aqueous dispersion is devoid of detergents and organic solvents.6. The method of where the aqueous dispersion consists of saline or water and the at least one functional-lipid construct.7. The method of where the lipid is a di-acyl glycerophospholipid.8. The method of where the lipid is a phosphatidylethanolamine.9. The method of where the lipid is a di-oleoyl phosphatidyl-ethanolamine.10. The method of where the functional moiety is cyanoselenide.11. The method of where the antimicrobial surface treatment is an antibacterial surface treatment.12. The method of where the antimicrobial surface treatment is a bactericidal surface treatment.13. The method of where the contacting the surface is by immersing the object in the dispersion for a time sufficient to provide the antimicrobial surface treatment.14. The method of where the time is less than 60 seconds.15. The method of where the time is less than 30 seconds.16. The method of where the time is less than 10 seconds.17. The method of where the dispersion is sonicated whilst the object is immersed.19. The construct of where m is the integer 1 claim 18 , 2 or 4.20. The construct of where m is the integer 2 claim 19 , n is the integer 4 ...

Device for feeding a line through the skin of a patient

A device for feeding a line through the skin of a patient, wherein the line contains a photodynamic substance that releases highly reactive oxygen derivatives when irradiated. Thus, disinfection/sterilization can be achieved in the region of a feed-through both on the outside of the skin and in the feed-through region by irradiating the feed-through.

Therapeutic compositions of undecylenic acid and arginine

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.

Implantable Medical Instrument Made of Iron-Based Alloy and Manufacturing Method Therefor

An implantable medical instrument is made of an iron-based alloy, comprising an iron-based alloy substrate and a drug-loaded coating. The drug-loaded coating comprises a polymer and an active drug; the weight average molecular weight of the polymer is greater than or equal to 50,000 and less than or equal to 1,000,000; micro-pores having a diameter of less than or equal to 10 micrometers are formed in the drug-loaded coating; the percentage of the active drug released on the implantable medical instrument made of an iron-based alloy is greater than or equal to 4t 1/2 −1 and less than or equal to 6.9t 1/2 +63, wherein t ∈ (0, 28], and t represents sampling time/days.

LIQUID EMBOLICS

Described herein are formulations that transition from a liquid state to a solid state for use in the embolization of arteriovenous malformations (AVM's) and solid tumors. 1. An embolic composition comprising:a substantially stable biocompatible polymer comprising a reaction product of a first monomer including a polymerizable moiety having a biodegradable or biostable linkage to a visualization agent having at least one aromatic ring including at least one iodine atom and a second monomer including a polymerizable moiety and at least one hydroxyl group; anda non-physiological solution containing a pharmaceutical drug or therapeutic agent;wherein the substantially stable biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution.2. The embolic composition of claim 1 , wherein at least one of the at least one iodine atom is a radioactive isotope.3. The embolic composition of claim 2 , wherein the radioactive isotope is I claim 2 , I claim 2 , I claim 2 , I claim 2 , or a combination thereof.4. The embolic composition of claim 1 , wherein the pharmaceutical drug or therapeutic agent is doxorubicin claim 1 , irinotecan claim 1 , sunitinib claim 1 , sorafenib claim 1 , paclitaxel claim 1 , temozolomide claim 1 , oxaliplatin claim 1 , gemcitabine claim 1 , carmustine claim 1 , cyclophosphamide claim 1 , vinchristine claim 1 , an antibody claim 1 , or a combination thereof.5. The embolic composition of claim 1 , wherein the pharmaceutical drug or therapeutic agent is paclitaxel.6. The embolic composition of claim 1 , wherein the pharmaceutical drug or therapeutic agent is irinotecan.7. The embolic composition of claim 1 , wherein the pharmaceutical drug or therapeutic agent is doxorubicin.8. The embolic composition of claim 1 , wherein the pharmaceutical drug or therapeutic agent is sunitinib.9. The embolic composition of claim 1 , wherein the pharmaceutical drug or therapeutic agent is sorafenib.10. The embolic ...

FUNCTIONALIZING NANOFIBRES

Methods for functionalizing the surface of nanofiber substrates, including electrospun fibres and non-woven or woven mats of fibres are described. Functionalised nanofiber substrates presenting biologically active moieties such as biotin and saccharides are described. 115-. (canceled)16. A functionalized nanofibre comprising an electrospun admixture of a polymer and a water soluble synthetic construct of the structure F-S-L where F is a functional moiety , L is a lipid and S is a spacer linking F to L via covalent bonds.17. The functionalized nanofibre of where the polymer is cellulose acetate (CA) or poly[(2-propyl-1 claim 16 ,3-dioxane-4 claim 16 ,6-diyl)methylene] (PVB).18. The functionalized nanofibre of where F is a functional moiety selected from the group consisting of: fluorophores of fluorescein claim 17 , biotin claim 17 , monosaccharides claim 17 , disaccharides claim 17 , trisaccharides and oligosaccharides.19. The functionalized nanofibre of where L is a phosphatidyl-ethanolamine. The invention relates to a method of functionalising the surface of nanofibre substrates. The substrates may take the form of either individual fibres or mats of non-woven or woven fibres. In particular, the invention relates to electrospun nanofibre substrates functionalised to present biologically active moieties at their surface.Functionalized nanofibres and matrices have potential in numerous biomedical applications including tissue engineering, wound dressing, drug delivery and enzyme immobilization. Electrospinning is a method commonly used in the preparation of such nanofibres and matrices.The publication of Kiick et al (2006) discloses functionalized electrospun matrices. In addition to the matrix polymer, the matrices comprise a compatibilizing polymer and a biomolecule or other small, functioning molecule. The biomolecule or other small functioning molecule is conjugated to an intermediate molecular weight polymer; the “compatibilizing polymer”. This attachment is ...

Insulin-Mimetic Composite for Bone Repair

The present disclosure generally relates to a composite scaffold containing insulin-mimetic materials for healing bone defects (e.g., bone repair). In particular, the present disclosure relates to a fibrous composite containing a synthetic polymer, nanoceramic and a vanadium salt to improve the healing of bone defects. 1. A composite scaffold capable of supporting cell and tissue growth comprising:(i) a synthetic polymer, wherein the synthetic polymer is formed into a plurality of fibers;(ii) at least one nanoceramic; and(iii) an insulin-mimetic compound,wherein the scaffold contains about 0.01 to about 0.1 wt % of the insulin-mimetic compound.2. The composite scaffold of claim 1 , further comprising mesenchymal stem cells.3. The composite scaffold of claim 1 , further comprising whole bone marrow.4. The composite scaffold of claim 1 , wherein the synthetic polymer is selected from the group consisting of polylactic acid claim 1 , poly L-lactic acid claim 1 , polyglycolic acid claim 1 , polylactic co-glycolic acid claim 1 , poly ε-caprolactone claim 1 , poly methacrylate co-n-butyl methacrylate claim 1 , poly dimethyl siloxane claim 1 , polyethylene oxide and combinations thereof.5. The composite scaffold of claim 1 , wherein the synthetic polymer is poly ε-caprolactone.6. The composite scaffold of claim 1 , wherein the scaffold contains about 65 to about 75 wt % of the synthetic polymer.7. The composite scaffold of claim 1 , wherein the at least one nanoceramic is selected from the group consisting of hydroxy apatite claim 1 , tricalcium phosphate claim 1 , biphasic calcium phosphate claim 1 , calcium carbonate claim 1 , calcium sulfate claim 1 , bioactive glass claim 1 , biphasic bioceramic and combinations thereof.8. The composite scaffold of claim 1 , wherein the at least one nanoceramic is a biphasic bioceramic hydroxyapatite/β-tricalcium phosphate.9. The composite scaffold of claim 1 , wherein the scaffold contains about 25 to about 35 wt % of the at least one ...

BIOADHESIVE POLYMER-BASED CONTROLLED-RELEASE SYSTEMS, PRODUCTION PROCESS AND CLINICAL USES THEREOF

The invention relates to release systems based on bioadhesive polymers, their manufacturing process and to their uses in the medical, pharmaceutical, cosmetic, cosmeceutical and nutraceutical fields. In particular, these release systems are provided for local application onto skin and mucosal lesions, in particular for the treatment of pathologies of the buccal mucosa. 1. A release system comprising a bioadhesive polymer or polymer mixture and a percentage of cyclodextrin in weight with respect to the polymer which ranges from 10 to 70% , preferably about 50% , characterized by the fact that the cyclodextrin forms a molecular dispersion with the polymer or polymer mixture and shows a decrease in the crystallinity measured as fusion enthalpy , at least 20% lower with respect to the polymer or polymer mixture alone.2. The release system according to claim 1 , wherein the polymer is chosen from among polyacrilic acids claim 1 , polyvinyl alcohol claim 1 , cellulose semi-synthetic derivatives claim 1 , starch hydrophilic derivatives claim 1 , alginates claim 1 , pectine claim 1 , chitosan claim 1 , polysaccharides claim 1 , natural gums claim 1 , polyethylene oxides claim 1 , preferably polyethylene oxides having a molecular weight higher than 600 kDa claim 1 , more preferably in a 50% mixture with a polyethylene oxide having a molecular weight higher than 4000 kDa claim 1 , and mixtures thereof.3. The release system according to - claim 1 , wherein the cyclodextrins are β-ciclodestrin and derivatives thereof claim 1 , preferably HP-beta-CD and methyl-beta-CD.4. The release system according to - claim 1 , further comprising an active principle chosen from among antibiotics claim 1 , antimicrobial drugs claim 1 , steroidal and non-steroidal antinflammatory drugs claim 1 , antioxidants claim 1 , antivirals claim 1 , local anesthetics claim 1 , antimicotic drugs claim 1 , anticoagulants claim 1 , wound-healing drugs claim 1 , cytostatics claim 1 , bone stimulants claim 1 , ...

Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids

The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.